https://trial.medpath.com/news/1e88dce5a4c1f808/low-dose-antithymocyte-globulin-shows-promise-for-type-1-diabetes-treatment-in-youth 2025-09-19T01:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/88237ecc9c278ca6/roche-acquires-89bio-to-expand-cardiometabolic-pipeline-beyond-glp-1-competition 2025-09-19T01:14:07+00:00 hourly 0.9 https://trial.medpath.com/news/a3d77869218ef2aa/moderna-settles-patent-dispute-with-alnylam-over-covid-19-vaccine-technology 2025-09-19T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/98c753be76a3b563/cevostamab-consolidation-after-car-t-therapy-shows-93-mrd-negative-response-rate-in-heavily-pretreated-multiple-myeloma 2025-09-19T01:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/0480b3247e4b32fd/vertex-secures-italian-reimbursement-for-crispr-gene-therapy-casgevy-expanding-european-access-for-blood-disorders 2025-09-19T01:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/9f259ec6f5373dca/biotech-stocks-surge-after-hours-as-investors-anticipate-key-clinical-trial-results 2025-09-19T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/d7342b9b49acf9b0/weill-cornell-medicine-receives-20-8-million-nih-grant-to-develop-childhood-hiv-vaccine 2025-09-19T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/5b19f8fa7ee22218/gerd-pipeline-shows-promise-with-novel-p-cab-therapies-advancing-through-late-stage-trials 2025-09-19T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/f586a3c405bf38d0/mink-therapeutics-appoints-dr-terese-hammond-to-lead-inkt-cell-therapy-pipeline-toward-pivotal-trials 2025-09-18T21:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/082b577b75b35b6c/celltrion-launches-first-omalizumab-biosimilar-omlyclo-in-europe-starting-with-norway 2025-09-18T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/a40f9e30c585a794/nt-301-nasal-spray-shows-promising-phase-1-results-for-parkinson-s-disease-off-episodes 2025-09-18T21:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/e1fd050e1dd07dc4/trevi-therapeutics-presents-nalbuphine-er-data-at-major-respiratory-conferences-following-positive-phase-2-trials 2025-09-18T21:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/309eb54d9d12d040/vectory-therapeutics-secures-1-2b-deal-for-shape-s-brain-penetrant-aav-capsid-technology 2025-09-18T21:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/25ef29bec718b987/gene-therapy-demonstrates-promise-as-one-time-treatment-for-alpha-thalassemia 2025-09-18T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/4fd15a923bfcf0ea/med-safety-mobile-app-increases-adverse-drug-reaction-reporting-by-73-in-uganda-trial 2025-09-18T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/21c6aa39af5b66d2/formation-bio-strengthens-leadership-team-with-former-pfizer-and-benevolentai-executives-to-advance-ai-driven-drug-development 2025-09-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/a6f21551a850fc22/kelyniam-global-receives-first-fda-clearance-for-bcp-peek-cranial-implants-in-eight-years 2025-09-18T21:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/841a9cfa23fbd327/fda-expands-hydrogen-peroxide-use-in-food-production-opening-new-market-for-tomi-s-steramist-technology 2025-09-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/6085b87f66b6fad2/stryker-opens-140000-square-foot-r-d-innovation-center-in-bengaluru-to-advance-medical-technology 2025-09-18T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9caf59e1292ad7f/early-hormone-therapy-reduces-alzheimer-s-risk-by-32-in-postmenopausal-women-new-meta-analysis-shows 2025-09-18T19:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/033bb47e60489d33/iveena-secures-2-million-nih-grant-to-advance-first-in-class-pediatric-myopia-eye-drop 2025-09-18T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/9e5225c3b9f9420a/semaglutide-demonstrates-significant-metabolic-benefits-in-schizophrenia-patients-on-antipsychotic-therapy 2025-09-18T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/025b19e72bd931e1/merck-invests-eur150-million-in-advanced-filtration-manufacturing-facility-in-ireland 2025-09-18T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/b00401226810f571/advanced-drug-delivery-technologies-drive-biotech-innovation-as-nanomedicine-market-approaches-430-billion 2025-09-18T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/62952c60e709247b/geneos-therapeutics-reports-five-year-recurrence-free-survival-in-aggressive-brain-and-liver-cancer-patients-with-personalized-immunotherapy 2025-09-18T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/2c6f924e09e3c372/cullgen-completes-phase-1-enrollment-for-novel-non-opioid-pain-therapy-cg001419 2025-09-18T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/6f8816524b21b166/nkgen-biotech-to-present-troculeucel-clinical-data-for-alzheimer-s-disease-at-major-international-conferences 2025-09-18T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/97bd2f78a6a124b9/atai-life-sciences-secures-11-4-million-nih-grant-for-non-hallucinogenic-opioid-use-disorder-treatment 2025-09-18T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/33913420f8881f23/humacyte-plans-q4-ind-filing-for-coronary-tissue-engineered-vessel-following-promising-primate-study 2025-09-18T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/84907e15aec99530/biogen-acquires-alcyone-therapeutics-for-85m-to-advance-implantable-drug-delivery-system-for-neurological-therapies 2025-09-18T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/5727ce27880c988b/argenx-expands-partnership-with-fujifilm-biotechnologies-to-manufacture-efgartigimod-in-the-u-s 2025-09-18T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/70543dc1cabde991/alk-partners-with-gensci-to-overcome-chinese-regulatory-challenges-and-expand-into-immunotherapy 2025-09-18T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/b6f14356432fd1fc/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-to-accelerate-rnai-drug-development 2025-09-18T17:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/2b3bf5a11dfdc107/organox-receives-fda-approval-for-air-transport-of-liver-perfusion-device-expanding-transplant-access-nationwide 2025-09-18T17:12:09+00:00 hourly 0.9 https://trial.medpath.com/news/07f3d979092b0acb/hong-kong-introduces-fast-track-drug-approval-system-to-reduce-review-time-by-33 2025-09-18T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/93d4e8af4378ac45/marengo-therapeutics-advances-phase-2-expansion-of-invikafusp-alfa-trodelvy-combination-for-metastatic-breast-cancer 2025-09-18T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/ddfb5c1c0618b869/fda-approves-three-novel-hae-therapies-in-2025-ending-four-year-regulatory-drought 2025-09-18T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/c005045abbb6bf4e/brainlab-receives-fda-clearance-for-spine-mixed-reality-navigation-system 2025-09-18T17:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/368a2a9f4ac8161b/chinese-drugmaker-jiangsu-hengrui-becomes-world-s-top-clinical-trial-sponsor-as-china-transforms-global-r-d-landscape 2025-09-18T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/db0d10d7c43c5c12/closed-loop-medicine-launches-first-personalized-glp-1-dosing-platform-to-combat-high-discontinuation-rates 2025-09-18T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/be26308c5e9da819/mavenclad-shows-sustained-long-term-benefits-in-multiple-sclerosis-with-four-year-data-at-ectrims-2025 2025-09-18T13:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/8e8c6945eb6b08ef/ovation-science-and-skinvisible-expand-thc-v-partnership-for-obesity-treatment-with-novel-transdermal-delivery-technology 2025-09-18T13:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/223c1e2ce420eaf4/immuto-scientific-secures-8m-funding-and-daiichi-sankyo-partnership-to-advance-ai-driven-cancer-target-discovery 2025-09-18T13:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/91ad7cfe0a08b1a4/fda-approves-updated-airsupra-label-showing-46-reduction-in-asthma-attacks-for-mild-asthma-patients 2025-09-18T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/5bafec9086268010/biocardia-s-cardiamp-cell-therapy-shows-82-reduction-in-angina-episodes-in-chronic-myocardial-ischemia-trial 2025-09-18T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/04e7b97656338f0d/roche-acquires-89bio-for-3-5-billion-to-strengthen-mash-treatment-pipeline 2025-09-18T13:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/c700fa906057d942/greenwich-lifesciences-expands-flamingo-01-breast-cancer-trial-to-ireland-adding-to-global-network-of-150-sites 2025-09-18T13:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/ba9b51c99ef81bf8/cphi-frankfurt-2025-reveals-pharma-awards-finalists-highlighting-industry-innovation-and-sustainability 2025-09-18T10:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/7df8c6d33c5f8316/metformin-s-brain-mechanism-revealed-after-60-years-new-pathway-could-transform-diabetes-treatment 2025-09-18T09:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/c839fcf8cf6c340f/st-jude-researchers-develop-novel-combination-therapy-to-overcome-neuroblastoma-treatment-resistance 2025-09-18T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/27b5f82058b3305a/ucb-s-galvokimig-shows-promise-in-phase-1-2a-trial-for-moderate-to-severe-atopic-dermatitis 2025-09-18T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/f49d25c73714095e/portuguese-startup-mondego-bio-secures-series-a-funding-to-develop-novel-ptpn2-inhibitors-for-cancer-immunotherapy 2025-09-18T09:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/36713916da0abbbd/genetic-test-predicts-semaglutide-response-in-post-bariatric-surgery-patients 2025-09-18T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/643eaf97eacb779d/corestemchemon-s-neuronata-r-shows-significant-benefits-in-als-slow-progressors-in-phase-3-trial 2025-09-18T09:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/0103ef1dd170dbd7/cocoa-extract-supplements-reduce-key-inflammatory-marker-in-large-clinical-trial 2025-09-18T05:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/22c1d4e339124139/stryker-and-siemens-healthineers-partner-to-develop-robotic-neurovascular-system-for-stroke-and-aneurysm-treatment 2025-09-18T05:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/b89467ec06ae2231/carsgen-s-zevor-cel-shows-exceptional-5-year-survival-data-in-relapsed-multiple-myeloma-patients 2025-09-18T05:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/28ca327a5247ddce/fda-reversal-threatens-access-to-promising-duchenne-muscular-dystrophy-cell-therapy 2025-09-18T05:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/8b4ce527e5183f4b/nanobiotix-s-jnj-1900-shows-promising-results-in-anti-pd-1-resistant-melanoma-patients 2025-09-18T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/158efbf4117dac21/magicrna-s-in-vivo-car-t-therapy-hn2301-shows-promise-in-first-in-human-lupus-trial 2025-09-18T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/a53b2fe80bbd2eb4/arsenal-biosciences-cuts-50-of-workforce-despite-325m-series-c-funding-round 2025-09-18T01:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/da96f3aaadd64eb3/cdc-advisory-panel-delays-controversial-vote-on-newborn-hepatitis-b-vaccine-timing 2025-09-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebc7fd5977c18cee/fda-approves-first-lamotrigine-oral-suspension-for-epilepsy-and-bipolar-disorder-treatment 2025-09-17T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/2790c3696e691266/chronic-lower-back-pain-pipeline-shows-mixed-results-as-multiple-phase-iii-trials-report-outcomes 2025-09-17T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/bd2ffc96f07437fb/crown-bioscience-opens-advanced-oncology-model-development-center-in-north-carolina 2025-09-17T21:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/b8d7c4e79a9c6810/swiss-researchers-develop-dual-action-fusion-protein-for-enhanced-cancer-immunotherapy 2025-09-17T21:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/2c63222eac929520/elranatamab-consolidation-therapy-shows-promise-in-deepening-response-after-car-t-treatment-in-multiple-myeloma 2025-09-17T21:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/72d2b251b6548475/eribulin-pyrotinib-combination-shows-promise-in-trastuzumab-resistant-her2-breast-cancer 2025-09-17T21:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/c4d89d1fc4d4d0a3/wheeler-bio-partners-with-mindimmune-to-advance-first-in-class-alzheimer-s-therapy-miti-101 2025-09-17T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/a8313ccbf9812712/oruka-therapeutics-orka-001-shows-100-day-half-life-in-phase-1-trial-potentially-enabling-annual-dosing-for-psoriasis 2025-09-17T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/5a2dc89f51ea4eef/changchun-high-tech-secures-eur177-7-million-deal-for-alk-s-house-dust-mite-allergy-immunotherapies-in-china 2025-09-17T21:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/d4a2e703dce72e22/bio-protocol-raises-6-9m-to-launch-ai-native-decentralized-science-platform-for-drug-discovery 2025-09-17T21:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/17bfeb821c31d429/daiichi-sankyo-receives-fda-breakthrough-therapy-designation-for-r-dxd-in-ovarian-cancer 2025-09-17T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/427fedf9cc1b9c40/arthex-biotech-secures-87m-series-b-to-advance-novel-rna-therapy-for-myotonic-dystrophy-type-1 2025-09-17T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/c0a485ed8b556601/rgenta-therapeutics-receives-fda-orphan-drug-designation-for-rgt-61159-in-adenoid-cystic-carcinoma-treatment 2025-09-17T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/8c3cb028f75e8200/nurix-and-gilead-s-irak4-degrader-gs-6791-shows-promise-for-inflammatory-skin-diseases-in-preclinical-studies 2025-09-17T17:22:13+00:00 hourly 0.9 https://trial.medpath.com/news/79474a91df320148/character-biosciences-secures-110m-series-b-extension-expands-leadership-to-advance-amd-therapeutics 2025-09-17T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/fd03ec96eecfece4/enveric-biosciences-publishes-breakthrough-research-on-microbial-bioproduction-of-neuropsychiatric-compounds 2025-09-17T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/e24898d3eda99564/tatum-bioscience-s-nanofilament-immunotherapy-tat003-demonstrates-strong-antitumor-activity-in-preclinical-study 2025-09-17T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/9d420da0410fd9ca/regeneron-s-garetosmab-achieves-90-reduction-in-bone-formation-in-rare-disease-trial 2025-09-17T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/aaf91200aeba5164/askbio-completes-enrollment-in-phase-1-gene-therapy-trial-for-rare-neurological-disease-msa-p 2025-09-17T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/3d54962c77f56d87/leo-pharma-s-temtokibart-meets-primary-endpoint-in-phase-2b-atopic-dermatitis-trial 2025-09-17T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/bb9493df324e730b/luxa-biotechnology-reports-significant-vision-gains-in-first-in-human-stem-cell-trial-for-dry-amd 2025-09-17T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/0984299a1063bb29/mapi-pharma-initiates-phase-i-ii-trial-for-once-monthly-cariprazine-depot-injection 2025-09-17T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/34ccc0482eb1bee4/arch-biopartners-acquires-novel-il-32-platform-for-chronic-kidney-disease-treatment 2025-09-17T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/3dc8bcecde538a96/visionary-holdings-partners-with-yike-regenerative-medicine-to-advance-anti-aging-biotechnology 2025-09-17T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/18ccf784a4dbb2c0/purdue-pharma-s-tinostamustine-enters-phase-2-3-gbm-agile-trial-for-glioblastoma-treatment 2025-09-17T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/d503a61cae3fd9e9/ollin-biosciences-emerges-with-100m-to-challenge-leading-eye-disease-treatments 2025-09-17T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/a61120c2ef14c18f/mabwell-and-aditum-bio-launch-kalexo-bio-to-advance-novel-sirna-therapy-for-cardiovascular-disease 2025-09-17T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/f122f3bdd75042d6/first-digital-cbt-therapeutic-for-menopause-shows-significant-symptom-reduction-in-clinical-trial 2025-09-17T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/7575bad08755155c/glp-1-drugs-alter-taste-perception-enhancing-sweetness-and-saltiness-to-support-appetite-control 2025-09-17T13:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/ce4932722fa0387a/navigator-medicines-reports-positive-phase-1a-safety-data-for-dual-target-bispecific-antibody-nav-240 2025-09-17T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e74b5f6f94d2b1b/brepocitinib-achieves-first-ever-positive-phase-3-results-in-dermatomyositis-setting-new-treatment-standard 2025-09-17T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/dafba1644a031ed1/uk-secures-zero-tariff-us-deal-and-increases-medicine-investment-to-accelerate-patient-access-to-breakthrough-treatments 2025-09-17T13:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/d77334f11f56b34b/amber-implants-receives-fda-510-k-clearance-for-vcfix-spinal-system-to-treat-vertebral-compression-fractures 2025-09-17T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/21994f373512e86a/microbiotica-completes-recruitment-for-phase-1b-trial-of-microbiome-therapy-mb097-in-treatment-resistant-melanoma 2025-09-17T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/3aea161940afb831/astrazeneca-s-saphnelo-subcutaneous-formulation-meets-primary-endpoint-in-phase-iii-lupus-trial 2025-09-17T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/a36b748ee05f2f50/uhnm-becomes-first-uk-site-to-recruit-patient-for-biontech-s-phase-3-small-cell-lung-cancer-trial 2025-09-17T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/68aef46d9c775742/ernexa-therapeutics-to-present-breakthrough-erna-101-cell-therapy-data-at-aacr-ovarian-cancer-conference 2025-09-17T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/00107b3ad0affb13/innate-pharma-advances-key-pipeline-assets-while-implementing-strategic-restructuring 2025-09-17T09:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/dfcb5ce6f3b6868e/vietnam-achieves-first-successful-car-t-cell-therapy-treatment-for-pediatric-acute-leukemia 2025-09-17T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/9b17efee30f2a316/tonix-pharmaceuticals-licenses-long-acting-monoclonal-antibody-tnx-4800-for-seasonal-lyme-disease-prevention 2025-09-17T09:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/9835415bce20e55a/incyte-s-povorcitinib-shows-sustained-efficacy-in-phase-3-hidradenitis-suppurativa-trials-through-24-weeks 2025-09-17T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/98ffaad4418bba88/piramal-pharma-solutions-enhances-manufacturing-capabilities-with-advanced-bilayer-tablet-press-technology 2025-09-17T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/b60a1ee5d52382bb/fda-issues-warning-letters-to-eli-lilly-novo-nordisk-and-hims-over-misleading-weight-loss-drug-advertising 2025-09-17T09:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/d3b37ff0837b6ca1/co-diagnostics-forms-joint-venture-with-saudi-arabian-partner-to-manufacture-pcr-diagnostics-platform 2025-09-17T09:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/965884761a3561e4/scienture-s-arbli-becomes-first-fda-approved-ready-to-use-liquid-losartan-securing-major-market-access 2025-09-17T05:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/e2851ca9a2a2d487/hightide-therapeutics-htd1801-achieves-primary-endpoint-in-phase-3-type-2-diabetes-trial 2025-09-17T05:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/5d26f69febb47c61/eisai-s-tau-antibody-etalanetug-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-09-17T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/7f555dab6d07f696/cytokinetics-raises-650-million-through-convertible-notes-to-fund-aficamten-commercial-launch 2025-09-17T01:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/09804c6744350bf5/auravax-secures-gates-foundation-grant-for-nanosting-001-influenza-challenge-study 2025-09-17T01:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/9e67700a5f834fda/polypid-passes-fourth-consecutive-gmp-inspection-advances-d-plex100-toward-2026-nda-submission 2025-09-17T01:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/0e0b7e2ea6c4d50d/nxera-pharma-advances-novel-ep4-antagonist-htl0039732-to-phase-2a-trial-for-advanced-solid-tumors 2025-09-17T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/15b280b8ce7ae20f/british-columbia-opens-first-phase-1-clinical-trials-unit-for-non-oncology-treatments 2025-09-17T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/a7e22475eb579e24/neurocrine-biosciences-advances-osavampator-to-phase-3-following-positive-depression-trial-results 2025-09-17T01:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/cfc47e7480b04a0e/gsk-commits-30-billion-u-s-investment-to-advance-respiratory-and-cancer-medicine-manufacturing 2025-09-17T01:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/0152f47b56a9ad60/ir-med-s-pressuresafe-technology-advances-through-clinical-trials-targeting-26-8b-pressure-injury-market 2025-09-16T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/605772082d35a400/utr-therapeutics-publishes-preclinical-data-for-first-in-class-c-myc-rna-therapeutic-utrxm1-18 2025-09-16T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/f28aff8419d496d4/landmark-trial-confirms-shunt-surgery-benefits-for-older-adults-with-hydrocephalus 2025-09-16T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/c8b8bb5f985869d7/blood-tests-show-promise-for-early-als-detection-years-before-symptoms-appear 2025-09-16T21:15:06+00:00 hourly 0.9 https://trial.medpath.com/news/926b4c8219892795/yokogawa-and-repligen-partner-to-advance-real-time-bioprocess-monitoring-technology 2025-09-16T21:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/7e0fc65bdbbdc23e/roche-integrates-ai-enabled-accu-chek-smartguide-cgm-with-mysugr-app-following-ce-mark-approval 2025-09-16T21:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/d5baff6f09f155e0/china-approves-first-drug-patent-term-extensions-marking-new-era-for-pharmaceutical-ip-protection 2025-09-16T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/e718b2489f2793b9/gout-drug-pipeline-expands-with-25-novel-therapies-as-companies-target-unmet-medical-needs 2025-09-16T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/824a532f5caf60c2/cantoni-therapeutics-secures-funding-to-advance-novel-nnmt-inhibitor-for-obesity-treatment 2025-09-16T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/2888e6cabc773dcc/bristol-myers-squibb-divests-historic-china-joint-venture-stake-to-focus-on-innovation 2025-09-16T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/797774c0773a6477/autolus-therapeutics-reports-promising-safety-profile-for-car-t-therapy-in-severe-lupus-patients 2025-09-16T17:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/d7f204a764d17495/prt120-peanut-oral-immunotherapy-demonstrates-durable-3-year-remission-in-phase-2b-study 2025-09-16T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/1e85f676a8d85caf/gaiaso-appoints-dr-tracey-brown-as-ceo-to-advance-precision-radiopharmaceuticals-for-women-s-cancers 2025-09-16T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/341abb9a87245ea3/enveric-biosciences-advances-eb-003-depression-treatment-directly-to-ind-submission-following-fda-guidance 2025-09-16T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/fd8a4155be99e453/ocugen-shares-surge-16-5-following-exclusive-korean-licensing-deal-for-ocu400-gene-therapy 2025-09-16T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/7c683388f1683c69/berlin-center-for-gene-and-cell-therapies-breaks-ground-creating-european-hub-for-advanced-therapeutics 2025-09-16T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/7b22d00a7293526e/adaptimmune-s-tecelra-marks-first-engineered-cell-therapy-approval-for-solid-tumors-in-synovial-sarcoma 2025-09-16T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/638a1efb6927875a/allrock-bio-secures-50-million-series-a-to-advance-first-in-class-pan-rock-inhibitor-for-pulmonary-hypertension 2025-09-16T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/6d6e8f59b06cafe7/aptevo-s-mipletamig-achieves-100-remission-rate-in-phase-1b-2-aml-trial 2025-09-16T17:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/6f83a69a25b94d04/dualitas-therapeutics-emerges-from-stealth-with-65m-series-a-to-advance-bispecific-antibody-pipeline 2025-09-16T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/007b23b117c3a920/nuclidium-s-copper-based-pet-tracer-shows-promise-in-phase-i-ii-trial-for-neuroendocrine-tumor-detection 2025-09-16T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/4c0bc846d37567d5/areteia-s-dexpramipexole-achieves-primary-endpoint-in-phase-iii-eosinophilic-asthma-trial 2025-09-16T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/55817e71d90efe11/fda-grants-fast-track-designation-to-crb-701-adc-for-recurrent-head-and-neck-cancer 2025-09-16T17:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/897d5ac7af11ec04/patensee-receives-fda-breakthrough-device-designation-for-ai-driven-hemodialysis-monitoring-system 2025-09-16T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/806e60c270f1d53c/lilly-commits-5-billion-to-virginia-manufacturing-facility-for-bioconjugate-and-adc-production 2025-09-16T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/6e8246ca6431b970/dr-reddy-s-launches-next-generation-acid-blocker-tegoprazan-in-india-following-phase-iii-success 2025-09-16T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/d692267733f865ad/metis-techbio-launches-ai-powered-nanoforge-platform-to-transform-drug-delivery 2025-09-16T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/82b33cc188183bc3/cook-myosite-advances-phase-iii-cell-therapy-trial-for-chronic-fecal-incontinence-in-women 2025-09-16T13:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/393af27f9aa74469/metabolic-surgery-demonstrates-superior-long-term-outcomes-over-glp-1-receptor-agonists-in-diabetes-and-obesity 2025-09-16T13:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/127d1390f36a1af9/nice-approves-durvalumab-for-limited-stage-small-cell-lung-cancer-first-treatment-advance-in-over-30-years 2025-09-16T13:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/692e681bbe5a3118/fluoguide-receives-fda-alignment-for-fg001-intraoperative-imaging-agent-in-high-grade-glioma 2025-09-16T13:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/8795d33a8b0c7362/aprecia-partners-with-apprentice-io-to-scale-ai-powered-3d-pharmaceutical-manufacturing 2025-09-16T13:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/440f7d4c4229d53c/zyvet-launches-first-fda-approved-generic-phenylpropanolamine-for-canine-urinary-incontinence 2025-09-16T13:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/57e2ab8644aee5ca/fda-approves-first-medical-device-for-asherman-syndrome-addressing-major-cause-of-female-infertility 2025-09-16T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/3926b25570aeac84/tenax-therapeutics-secures-european-patent-protection-for-levosimendan-in-ph-hfpef-through-2040 2025-09-16T13:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/adc66a0606431f60/aicuris-reports-positive-phase-2-results-for-pritelivir-in-refractory-hsv-infections-and-favorable-phase-1-safety-data-for-aic468 2025-09-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/c096b112c87fd607/henlius-biotech-in-advanced-licensing-talks-with-j-j-and-roche-for-experimental-cancer-drug 2025-09-16T09:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/a0351fc378ae31da/ferroptosis-inducing-drug-auranofin-shows-promise-in-combination-with-chemotherapy-for-resistant-neuroblastoma 2025-09-16T09:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/a9db511ebcffc9d7/fda-grants-510-k-clearance-for-apollo-tms-device-to-treat-major-depressive-disorder-in-adolescents 2025-09-16T09:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/b76b25fc8a83bd56/race-oncology-discovers-novel-bisantrene-photoisomers-files-patent-applications-for-20-year-protection 2025-09-16T09:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/de75eed8cf04f1f3/fda-expands-vyjuvek-label-for-home-use-and-all-ages-boosting-krystal-biotech-s-market-potential 2025-09-16T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/c3bc7d877fa8a547/anacardio-completes-phase-2a-enrollment-for-heart-failure-drug-candidate-ac01 2025-09-16T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/974f8f91eae9fa4d/alpha-modus-expands-patent-enforcement-campaign-with-lawsuit-against-indian-ai-retail-company-allerin-tech 2025-09-16T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/684ebfb9be8cae6e/drug-hunter-secures-seed-investment-to-expand-knowledge-platform-for-pharmaceutical-r-d 2025-09-16T05:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/83b90a6eea701886/fda-set-to-review-five-key-pediatric-and-adult-therapies-in-q4-2025 2025-09-16T05:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/f686646c50e66763/race-oncology-secures-breakthrough-patent-protection-for-purified-bisantrene-cancer-drug 2025-09-16T05:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/c999588d8880eb9e/crism-therapeutics-advances-toward-phase-2-glioblastoma-trial-despite-widening-losses 2025-09-16T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/c4f9cf2033ce9a42/turn-therapeutics-prepares-for-nasdaq-debut-with-focus-on-dermatology-and-infectious-disease-programs 2025-09-16T01:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/7b4c1e119496b1e8/altimmune-appoints-linda-richardson-as-chief-commercial-officer-ahead-of-pemvidutide-phase-3-mash-trial 2025-09-16T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/44474289ad7c24d4/nyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-over-sleep-apnea-devices 2025-09-16T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/a91a65955b058d95/indian-patent-office-revokes-novartis-vymada-patent-opening-door-for-generic-competition 2025-09-16T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/2f640b388839e425/novo-nordisk-s-wegovy-shows-46-reduction-in-food-noise-and-improved-mental-health-in-real-world-survey 2025-09-16T01:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/66821fdc07ec84ff/mit-and-bidmc-teams-advance-novel-mrna-based-tuberculosis-vaccines-using-newly-identified-antigens 2025-09-16T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/b2a7e7ac0f5a8bb3/cook-medical-and-siemens-healthineers-launch-radiation-free-interventional-mri-suite-for-real-time-minimally-invasive-procedures 2025-09-16T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/e5263e05cc0d48db/real-world-safety-analysis-reveals-new-adverse-events-for-fenfluramine-in-rare-epilepsy-syndromes 2025-09-15T21:13:52+00:00 hourly 0.9 https://trial.medpath.com/news/2306036cdb950080/atyr-pharma-s-efzofitimod-fails-phase-3-trial-for-pulmonary-sarcoidosis 2025-09-15T21:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/77d71cdb7df17aa8/meta-analysis-shows-glp-1-receptor-agonists-effective-for-pediatric-obesity-and-type-2-diabetes 2025-09-15T21:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/9fa1f2a5091da0af/smith-nephew-s-regeneten-bioinductive-implant-receives-aaos-strong-recommendation-following-65-reduction-in-rotator-cuff-re-tear-rates 2025-09-15T21:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/1e3e993f765f1dfa/labconnect-and-omniscience-partner-to-launch-first-agentic-ai-platform-for-real-time-clinical-trial-lab-data-analysis 2025-09-15T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/8e5013c77541abf1/cms-finalizes-third-round-of-medicare-drug-price-negotiations-with-expanded-orphan-drug-exclusions 2025-09-15T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/b6e8e199936ab28f/parexel-forms-strategic-ai-partnerships-to-accelerate-drug-development-and-clinical-trial-efficiency 2025-09-15T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f0c12674d1488b3/proteonic-launches-2g-unic-transposon-platform-for-enhanced-biologics-production 2025-09-15T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/c1ff3a04a9f62765/federal-courts-uphold-state-340b-protection-laws-against-pharmaceutical-challenges 2025-09-15T17:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/e5926e7d5c8496a4/novartis-challenges-rhode-island-s-340b-drug-pricing-law-in-federal-court 2025-09-15T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/d37aa6ceba5a3a4f/serine-free-diet-shows-promise-in-slowing-glioblastoma-growth-and-enhancing-treatment-response 2025-09-15T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/0831b89534f4962a/mycenax-biotech-and-spera-pharma-form-strategic-alliance-to-enhance-adc-manufacturing-capabilities 2025-09-15T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/3403ef8b4972c595/humacyte-s-symvess-demonstrates-92-patency-rate-in-hospital-acquired-vascular-complications-study 2025-09-15T17:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/5f3c4f7e78f255f0/lindis-blood-care-s-catuvab-device-achieves-100-tumor-cell-removal-in-pivotal-cancer-surgery-study 2025-09-15T17:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/76eb4b95cf26365a/sohm-secures-south-korean-patent-for-crispr-based-gene-editing-platform-targeting-car-t-therapy-development 2025-09-15T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/edbfe02410a12892/gyala-therapeutics-advances-first-in-class-cd84-targeting-car-t-therapy-with-eur3-million-funding-for-aml-and-t-all-treatment 2025-09-15T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/0e8f4872d8ff5002/biparametric-mri-proves-noninferior-to-standard-multiparametric-mri-for-prostate-cancer-detection-in-prime-trial 2025-09-15T17:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/010b3babc85cc7a0/avalyn-pharma-unveils-aura-ipf-phase-2-trial-design-for-inhaled-nintedanib-at-ers-congress-2025 2025-09-15T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/780b8e86a4ea30b2/labcorp-completes-225-million-acquisition-of-bioreference-health-s-oncology-testing-assets 2025-09-15T17:21:56+00:00 hourly 0.9 https://trial.medpath.com/news/96cc0bbfc12880f5/made-scientific-partners-with-basilard-biotech-to-advance-nanomechanical-gene-delivery-platform-for-cell-therapies 2025-09-15T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/c67c245aec66e9c2/conceivable-life-sciences-raises-50-million-series-a-to-commercialize-ai-powered-automated-ivf-laboratory 2025-09-15T17:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/a16eb3c50c6c6753/abbvie-s-vraylar-achieves-full-provincial-coverage-in-canada-with-alberta-reimbursement-approval 2025-09-15T17:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/6307008386d3be35/inmune-bio-achieves-commercial-manufacturing-milestone-for-rdeb-cell-therapy-cordstromtm 2025-09-15T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/7e598959e140d237/johnson-johnson-presents-phase-3-data-for-seltorexant-in-major-depressive-disorder-at-2025-psych-congress 2025-09-15T17:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/7044aa1f77b85f80/emergent-biosolutions-secures-17-million-barda-contract-for-smallpox-antiviral-tembexa-oral-suspension 2025-09-15T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/9e82cfe097684a0c/fire-trial-shows-supraflex-cruz-stent-reduces-cardiovascular-events-in-elderly-heart-attack-patients 2025-09-15T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/f41ab790fcdfb4a0/cadrenal-therapeutics-acquires-exithera-s-factor-xia-inhibitor-portfolio-in-15m-deal 2025-09-15T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/ec544ddbb4ed9a8b/rona-therapeutics-files-ind-for-rn3161-novel-sirna-targeting-inhbe-for-obesity-treatment 2025-09-15T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/512265712a98b5db/protagonist-to-present-phase-2b-icotrokinra-data-for-ulcerative-colitis-at-european-gastroenterology-week 2025-09-15T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/f8e4cd92bee6d871/renalytix-partners-with-tempus-ai-to-expand-access-to-fda-approved-kidney-disease-risk-test 2025-09-15T17:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/e6b6b18e21ac33af/argo-biopharma-advances-sirna-therapy-bw-40202-to-phase-ii-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-09-15T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/7c45167ae3280284/biocartis-receives-fda-approval-for-first-fully-automated-companion-diagnostic-test-for-colorectal-cancer 2025-09-15T17:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/418a87f82007101e/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study 2025-09-15T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/5e01fba59c933633/biostar-pharma-initiates-two-phase-ii-iii-trials-for-utidelone-capsule-in-gastric-and-ovarian-cancers 2025-09-15T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/d9b73aa2ee02acbd/taiwan-s-glac-biotech-receives-fda-gras-approval-for-probiotic-strain-cp-9-expanding-infant-nutrition-portfolio 2025-09-15T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/37bbc37f776756b9/sagent-pharmaceuticals-enters-8-6-billion-ophthalmic-market-with-travoprost-launch 2025-09-15T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/d3ebc35a7aeb0da0/proofpilot-acquires-lokavant-to-enhance-clinical-trial-performance-with-ai-powered-predictive-analytics 2025-09-15T17:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/873d89a5aca88344/worldwide-clinical-trials-appoints-alistair-macdonald-as-new-ceo-following-peter-benton-s-retirement 2025-09-15T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/ec8b295454c3b3c3/uci-mind-receives-18-million-nih-grant-to-establish-first-trial-ready-cohort-for-late-dementia 2025-09-15T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/news/fbef25ddb6dc5910/icecure-medical-advances-cryoablation-technology-with-patent-approval-and-regulatory-clearance-for-xsense-system 2025-09-15T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/deaded006c1f329c/b-braun-completes-full-acquisition-of-true-digital-surgery-to-advance-digital-microsurgery-technology 2025-09-15T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/6cb7043d7a15b9b8/medtronic-launches-pivotal-trial-testing-personalized-pacing-therapy-for-heart-failure-patients 2025-09-15T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5dba695bcedf7e01/ondine-biomedical-s-steriwave-technology-shows-99-9-efficacy-against-drug-resistant-c-auris-as-european-cases-surge-67 2025-09-15T13:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/6b5462e9b30c1ef2/catalym-strengthens-leadership-team-to-advance-visugromab-through-late-stage-development 2025-09-15T13:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/94a98c0311fc6a14/kodiak-sciences-ksi-101-demonstrates-62-vision-improvement-in-phase-1b-mesi-trial 2025-09-15T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/234de7640e74fcae/genflow-biosciences-signs-cdas-with-animal-health-companies-to-advance-sirt6-gene-therapy-platform 2025-09-15T13:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/e1688b25f9ffc042/ocugen-partners-with-kwangdong-for-ocu400-gene-therapy-in-korea-with-7-5m-upfront-deal 2025-09-15T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/5fd060cee847c188/can-fite-reports-complete-resolution-of-esophageal-varices-in-decompensated-cirrhosis-patient-treated-with-namodenoson 2025-09-15T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/76124764c1f41380/som-biotech-secures-european-orphan-drug-designation-for-huntington-s-disease-therapy-som3355 2025-09-15T13:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/27734eccca9e6df2/international-research-team-secures-800000-to-advance-first-potentially-regenerative-multiple-sclerosis-treatment 2025-09-15T13:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/5ec923a2edef4383/curatis-advances-c-ptbe-01-toward-phase-iii-trial-following-positive-fda-meeting 2025-09-15T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/264717327fa59c0b/dexcom-unveils-smart-basal-feature-and-presents-clinical-evidence-at-easd-2025 2025-09-15T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/4cc296885ee9a959/novocure-s-optune-lua-receives-japanese-approval-for-advanced-nsclc-treatment 2025-09-15T13:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/23e7b10e039d084f/avita-medical-secures-ce-mark-for-recell-go-expanding-burn-treatment-access-across-europe 2025-09-15T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/news/1451aa030759fc2e/pfizer-advances-australian-discovered-kat6-inhibitor-pf-07248144-to-phase-3-trial-for-hr-her2-metastatic-breast-cancer 2025-09-15T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/83dc2bdc84f4b481/qlife-advances-two-home-diagnostic-tests-for-heart-failure-into-clinical-trials 2025-09-15T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/7c30a4afb50d8d4a/seven-real-world-studies-demonstrate-nefecon-s-efficacy-in-iga-nephropathy-treatment-across-diverse-patient-populations 2025-09-15T06:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/f22d31c8d44cfc9f/everbridge-group-secures-exclusive-japanese-market-partnership-with-cosmotec-for-medical-device-commercialization 2025-09-15T06:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/a6524da1027f451d/phrontline-biopharma-initiates-phase-1-trial-for-tj101-dual-target-adc-in-solid-tumors 2025-09-15T04:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/aae619993e0ac3bc/cleo-diagnostics-receives-positive-fda-feedback-for-ovarian-cancer-blood-test-advancing-toward-us-approval 2025-09-15T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/c7242c926104f9c1/lion-tcr-receives-fda-ind-clearance-for-first-in-class-tcr-t-therapy-targeting-chronic-hepatitis-b 2025-09-15T04:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/d2ea7cb3195f266e/agios-pharmaceuticals-faces-securities-fraud-investigation-following-fda-delay-of-pyrukynd-approval 2025-09-15T01:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/c740cc2dfe930b85/nurix-therapeutics-advances-bexobrutideg-phase-iii-program-and-expands-protein-degrader-pipeline 2025-09-14T21:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/92453c305949a14e/cocrystal-pharma-advances-antiviral-pipeline-with-13m-funding-cdi-988-enters-phase-1b-human-challenge-study 2025-09-14T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/5c3b859a13e6d509/monopar-s-alxn1840-shows-sustained-neurological-benefits-in-long-term-wilson-disease-study 2025-09-14T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/0f32b2be7b9aa932/breakthrough-hiv-antibody-04-a06-neutralizes-98-5-of-viral-strains-in-preclinical-studies 2025-09-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/a675e28a5b2b0d96/globe-biotech-secures-first-us-patent-for-bangladesh-with-single-dose-covid-19-mrna-vaccine 2025-09-14T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/85fb5e6e9874e925/alembic-pharmaceuticals-receives-usfda-clearance-for-api-manufacturing-facilities-following-may-inspection 2025-09-14T13:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/9914563f6ab9b9fd/indian-researchers-develop-cassava-starch-patches-for-oral-cancer-and-leukoplakia-treatment 2025-09-14T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/57529dd76dce7944/cdsco-approves-phase-i-trial-for-jeevan-scientific-s-bevacizumab-biosimilar-in-india 2025-09-14T09:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/748e2b04f401a505/takeda-partners-with-asian-hospital-to-expand-access-to-rare-disease-treatments-in-philippines 2025-09-14T05:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/9b4bf0a9f8e150bb/novocure-s-optune-lua-receives-fda-approval-for-metastatic-non-small-cell-lung-cancer-extending-survival-by-3-3-months 2025-09-14T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/5b52757512fd3d4c/indian-pharma-companies-leverage-fda-505-b-2-pathway-to-create-differentiated-generics-with-merck-support 2025-09-14T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/52b93c70ac4ad4bf/vietnam-and-russia-sign-major-biopharmaceutical-technology-transfer-agreement-for-advanced-drug-production 2025-09-14T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/2dd42e70415ee7fd/lila-sciences-achieves-unicorn-status-with-235m-funding-for-ai-driven-drug-discovery-platform 2025-09-14T01:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/a91e0079f5d5eabf/novo-nordisk-stock-deemed-undervalued-following-recent-fda-approval-and-market-decline 2025-09-14T01:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/179f65305e06562f/chinese-scientists-develop-revolutionary-bone-02-adhesive-that-heals-fractures-in-three-minutes 2025-09-13T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/80b8d557d2d49d24/johnson-johnson-stock-deemed-undervalued-following-recent-fda-approval-despite-20-8-annual-gains 2025-09-13T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/5043c25eef297ae2/apollo-hospitals-invests-rs-573-crore-in-advanced-proton-therapy-oncology-center-in-gurugram 2025-09-13T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/b55d76655dac5be9/fda-draft-guidance-on-non-opioid-pain-therapies-could-accelerate-apitox-development-for-osteoarthritis 2025-09-13T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/81f4c6f71e21a5d4/verona-pharma-and-vertex-pharmaceuticals-show-divergent-valuation-patterns-following-recent-fda-approvals 2025-09-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/a88ca716d7eba1ab/alligator-bioscience-presents-promising-preclinical-data-for-ator-4066-bispecific-antibody-at-cicon25 2025-09-13T13:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/5c953811fb70fcc6/real-world-lotus-study-shows-sustained-efficacy-of-daybue-in-rett-syndrome-patients-over-12-months 2025-09-13T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/9b7d17f3b013066c/mallinckrodt-wins-9-5m-patent-infringement-award-in-nitric-oxide-therapy-case 2025-09-13T10:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/75f029b379ab12d0/triastek-opens-world-s-largest-3d-printed-pharmaceutical-facility-in-china-targets-300-million-tablets-annually 2025-09-13T09:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/4e18685f066698ba/real-world-analysis-reveals-cardiac-failure-risk-varies-significantly-among-breast-cancer-therapies 2025-09-13T09:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/01f768241f607fd2/fore-biotherapeutics-reports-durable-clinical-benefit-with-plixorafenib-in-braf-altered-thyroid-cancers 2025-09-13T05:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/999053aeb36b7898/yoltech-therapeutics-secures-45-million-series-b-funding-to-advance-in-vivo-gene-editing-pipeline 2025-09-13T05:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/4e9810ba1801b643/musc-launches-clinical-trial-for-heart-safe-triple-negative-breast-cancer-treatment 2025-09-13T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/dc2a8905508f450c/novel-bispecific-antibody-combinations-show-promise-in-indolent-lymphoma-treatment 2025-09-13T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/32a28e71e9499b5e/agios-mitapivat-receives-positive-chmp-opinion-for-thalassemia-treatment-in-europe 2025-09-13T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/f8cb7b13d313c52e/uci-health-s-stopgap-ii-trial-advances-to-national-phase-for-advanced-gastric-cancer-treatment 2025-09-13T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/dfae6ffd1d5a44fe/rybrevant-plus-lazcluze-combination-demonstrates-superior-overall-survival-in-first-line-egfr-mutated-nsclc 2025-09-13T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/1e55c53e0fdcd9c3/uni-bio-science-group-partners-with-kexing-biopharm-to-expand-osteoporosis-treatment-bogutai-r-to-six-international-markets 2025-09-13T01:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/df367c5535a4efcf/fermenta-biotech-secures-patent-for-plant-based-vitamin-d3-production-technology 2025-09-12T21:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/53096eff7cc7ca09/australian-court-denies-preliminary-injunction-against-sandoz-aflibercept-biosimilar-launch 2025-09-12T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb02d679d74328ce/nevian-lifescience-launches-first-locally-manufactured-novartis-medicine-following-bangladesh-acquisition 2025-09-12T21:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/7698ea335be5f36b/oncotelic-therapeutics-reports-progress-across-six-late-stage-drug-programs-in-oncology-and-rare-diseases 2025-09-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/2342d7ec0d9c4a7c/novel-pcsk9-inhibitor-recaticimab-shows-54-ldl-cholesterol-reduction-in-phase-3-trial-for-familial-hypercholesterolemia 2025-09-12T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/7960140b80112699/zoetis-receives-eu-regulatory-nod-for-first-long-acting-feline-osteoarthritis-pain-treatment 2025-09-12T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/255f300cb5a1692f/fda-plans-to-present-data-linking-covid-19-vaccines-to-25-pediatric-deaths-at-cdc-advisory-meeting 2025-09-12T21:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/1b9342b6de001dd6/simris-biologics-secures-eur200k-grant-to-develop-novel-microcystin-based-adc-payloads-for-cancer-therapy 2025-09-12T17:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/e52d2e98bc970d9f/alx-oncology-appoints-barbara-klencke-as-interim-chief-medical-officer-to-advance-cancer-pipeline 2025-09-12T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/e931b184fd9401b2/galimedix-therapeutics-completes-phase-1-trial-of-oral-alzheimer-s-drug-gal-101 2025-09-12T17:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/56a83516a30798b3/gelteq-achieves-first-u-s-commercial-milestone-with-partner-s-nutraceutical-product-launch 2025-09-12T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/09ee7ef56fc0fcdd/pulnovo-medical-secures-fda-ide-approvals-for-padn-system-clinical-trials-with-cms-coverage 2025-09-12T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/31f87bfd46db3792/maia-biotechnology-s-ateganosine-shows-promising-efficacy-in-phase-ii-nsclc-trial 2025-09-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/497229e32d23a1ac/china-announces-national-hpv-vaccination-program-as-domestic-nine-valent-vaccine-launches 2025-09-12T13:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/fdccea7db059f210/fda-moves-to-eliminate-expert-advisory-panels-for-individual-drug-reviews-under-trump-administration 2025-09-12T13:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/88cec563233bb06e/united-therapeutics-to-present-phase-3-teton-2-data-for-inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-at-ers-congress 2025-09-12T13:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/774e3caa37674303/allterum-therapeutics-receives-fda-clearance-for-4a10-antibody-therapy-in-pediatric-leukemia 2025-09-12T13:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/e291d7adc2d849fe/city-of-hope-advances-novel-aml-therapies-and-unveils-breakthrough-research-at-ash-2025 2025-09-12T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/dccce21de4d43e84/meta-analysis-shows-anlotinib-improves-survival-and-response-rates-in-nsclc-brain-metastases 2025-09-12T13:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/40894268f3640d7e/inflammasome-therapeutics-k8-implant-reduces-geographic-atrophy-lesion-growth-by-53-in-phase-i-trial 2025-09-12T09:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/57cd1ecc86bd622c/sophont-raises-9-22-million-to-develop-multimodal-ai-platform-for-medical-diagnosis-and-drug-discovery 2025-09-12T09:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/c1c8e5f8c5fca646/polyrizon-s-intranasal-barrier-technology-shows-promise-against-respiratory-viruses-and-allergens 2025-09-12T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a39f8ead55206b2/achieve-life-sciences-appoints-dr-mark-rubinstein-as-interim-cmo-amid-cytisinicline-fda-review 2025-09-12T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/ad4919e9b813e50a/selinexor-triplet-therapy-shows-significant-survival-benefit-in-pi-naive-multiple-myeloma-patients 2025-09-12T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/e16726ccc277116b/world-gu-2025-highlights-advances-in-variant-histology-management-and-community-oncology-care-for-genitourinary-cancers 2025-09-12T02:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/86c8b1bee6a576e5/takeda-appoints-former-eli-lilly-executive-rhonda-pacheco-to-lead-u-s-operations 2025-09-12T01:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/629dc5b38723b8ae/vertex-scientists-win-prestigious-lasker-award-for-revolutionary-cystic-fibrosis-treatment 2025-09-12T01:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/fa5bbd6f52b5355f/samsung-biologics-secures-1-3-billion-us-manufacturing-deal-amid-trade-policy-uncertainty 2025-09-12T01:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/4d336922efa97645/biocon-inaugurates-first-us-manufacturing-facility-in-new-jersey-with-30-million-investment 2025-09-12T01:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/11e47c19e4888d18/ge-healthcare-acquires-icometrix-to-strengthen-brain-mri-analysis-capabilities-for-alzheimer-s-drug-monitoring 2025-09-12T01:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/694c6b4837d3f468/first-fully-digital-adhd-diagnostic-tool-validated-in-peer-reviewed-study 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/89a20fad7e6c6d51/fda-advisory-committee-establishes-framework-for-ai-powered-mental-health-chatbots 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e2cf0108888f7362/odyssey-therapeutics-raises-213m-series-d-to-advance-autoimmune-disease-pipeline-after-shelving-ipo-plans 2025-09-11T22:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/468f7c29704f27c2/trump-administration-withdraws-dea-marijuana-rules-clearing-path-for-fda-compliant-cannabis-trials 2025-09-11T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/4128ccc3727ffee9/intercept-pharmaceuticals-withdraws-ocaliva-from-u-s-market-following-fda-safety-directive 2025-09-11T21:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/2c4a312bcb8e5c67/gene-solutions-secures-patent-for-novel-mitochondrial-therapy-platform-targeting-neurological-diseases 2025-09-11T21:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/225d124776655a46/ose-immunotherapeutics-completes-enrollment-in-phase-2-trial-testing-tedopi-cancer-vaccine-combinations-for-nsclc 2025-09-11T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/281e2caeaa9d2c81/chinese-scientists-develop-nano-tagging-robot-for-enhanced-cancer-immunotherapy 2025-09-11T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/8e8260b1da3bd591/fda-grants-510-k-clearance-to-ai-powered-bone-health-technologies-for-orthopedic-care 2025-09-11T21:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/36ded7a6292619ba/federal-appeals-court-upholds-medicare-drug-price-negotiations-for-novo-nordisk-insulin-products 2025-09-11T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/6ea7aea5cdceb1c7/china-s-national-drug-price-negotiation-policy-dramatically-improves-access-to-innovative-medicines-while-reducing-costs-by-up-to-78 2025-09-11T21:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/0b957bec533f1ed5/amd-partners-with-oracle-and-absci-to-accelerate-ai-driven-drug-discovery-using-advanced-gpu-technology 2025-09-11T21:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/1ca3bb5cdcf406d8/large-taiwanese-study-reveals-mixed-safety-profile-for-long-term-atropine-use-in-childhood-myopia-treatment 2025-09-11T21:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/9a3fa9b0f8573b2e/tempus-ai-receives-fda-510-k-clearance-for-enhanced-cardiac-imaging-platform-with-t1-and-t2-mapping-capabilities 2025-09-11T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/fa8700aea3aa25b6/n-power-medicine-and-viecure-partner-to-transform-clinical-trial-access-in-community-oncology 2025-09-11T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/2e250a52c1f892f2/amneal-receives-fda-approval-for-generic-sodium-oxybate-breaking-jazz-pharmaceuticals-monopoly-in-narcolepsy-treatment 2025-09-11T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/64f18d4621f6ed9a/acne-drug-isotretinoin-shows-promise-for-treating-male-infertility-in-small-study 2025-09-11T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/bb03875c0ccb8246/energous-completes-5-million-financing-round-to-advance-wireless-power-technology 2025-09-11T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c43d2b46f57b61d/actuate-therapeutics-raises-17-25-million-to-advance-gsk-3b-inhibitor-for-difficult-to-treat-cancers 2025-09-11T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/e970d417fd5df209/teleflex-initiates-dubstent-diabetes-trial-testing-dual-device-strategy-for-diabetic-patients-undergoing-pci 2025-09-11T17:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/7ed945b574d61e8e/nutriband-raises-5-3-million-through-warrant-exercises-to-advance-aversa-fentanyl-abuse-deterrent-patch-toward-fda-submission 2025-09-11T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/50d1a625d46696d2/fibrobiologics-reports-breakthrough-results-for-single-dose-fibroblast-spheroid-therapy-in-chronic-psoriasis 2025-09-11T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/2329fdab1683beae/maze-therapeutics-mze782-shows-42-fold-increase-in-phenylalanine-excretion-in-phase-1-trial-for-pku-and-ckd 2025-09-11T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/5677dc2b57b484d0/profusa-partners-with-nvidia-to-develop-ai-powered-continuous-biomarker-monitoring-portal 2025-09-11T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/97df32106d76ac83/medicines-discovery-catapult-and-crown-bioscience-form-strategic-alliance-to-accelerate-radiopharmaceutical-development 2025-09-11T17:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/e508b86c5b99de95/intercept-pharmaceuticals-voluntarily-withdraws-ocaliva-from-us-market-following-fda-request 2025-09-11T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/820232396c1d59a0/roivant-sciences-gains-orphan-drug-designation-in-japan-for-mosliciguat-in-pulmonary-hypertension 2025-09-11T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/5e3fd98586720e31/charles-river-laboratories-forms-strategic-oncology-alliances-to-accelerate-cancer-immunotherapy-development 2025-09-11T17:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/2881d67aca80fe16/former-fda-hematologic-malignancies-leader-nicholas-richardson-joins-precision-for-medicine-as-vp-clinical-development 2025-09-11T17:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/f8f0676481b526bd/absci-partners-with-oracle-and-amd-to-accelerate-ai-driven-drug-discovery-platform 2025-09-11T17:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/9bd37038a7672e56/nanonewron-secures-2-5m-nih-grant-to-advance-blood-brain-barrier-crossing-tnf-alpha-inhibitor-for-alzheimer-s-disease 2025-09-11T13:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/124bb8d7be9d58d3/arrowhead-pharmaceuticals-files-patent-lawsuit-against-ionis-over-plozasiran-fcs-treatment 2025-09-11T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/e0e1e9fd00dd7091/bausch-lomb-s-envista-envy-iol-demonstrates-superior-visual-performance-in-pivotal-clinical-trial 2025-09-11T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/f4158283bc063fc0/merck-s-capvaxive-shows-superior-immune-response-in-high-risk-children-and-adolescents 2025-09-11T13:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/ef2a16280ef2944a/radiomedix-and-vect-horus-initiate-first-in-human-trial-of-blood-brain-barrier-crossing-radiotracer-for-glioblastoma-and-pancreatic-cancer 2025-09-11T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/e74761f9b76159c7/lundbeck-restructures-global-operations-exits-27-markets-through-strategic-partnership-model 2025-09-11T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/636a60499412e429/apple-watch-receives-fda-approval-for-hypertension-detection-feature-expected-to-identify-over-one-million-undiagnosed-cases 2025-09-11T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/3300c152c667e64c/musc-hollings-cancer-center-launches-automain-trial-testing-repurposed-drugs-for-recurrent-ovarian-cancer 2025-09-11T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec77d205f493c33b/minnesota-develops-innovative-learning-health-care-community-model-to-bridge-research-practice-gap 2025-09-11T10:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/e141fedefb7c88c8/dr-reddy-s-laboratories-acquires-johnson-johnson-s-stugeron-brand-for-50-5-million-to-expand-cns-portfolio 2025-09-11T09:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/5445d3307d24c451/tg-therapeutics-to-present-six-year-briumvi-data-at-ectrims-2025-showcasing-long-term-multiple-sclerosis-treatment-outcomes 2025-09-11T09:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/822c8b099a480993/camp4-therapeutics-secures-100-million-financing-to-advance-first-in-class-syngap1-treatment 2025-09-11T09:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/081b6f29fba60b89/arrowhead-pharmaceuticals-advances-two-breakthrough-rnai-therapeutics-into-clinical-trials 2025-09-11T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/440d6cfb4dfa5230/tagworks-pharmaceuticals-advances-tgw101-to-third-dose-level-in-phase-1-trial-for-solid-tumors 2025-09-11T09:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/e62e4b78206e5c94/bioxodes-reports-promising-phase-2a-results-for-biox-101-in-intracerebral-hemorrhage-treatment 2025-09-11T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/2553f236ca7c27e5/teva-and-medincell-s-long-acting-risperidone-injection-expands-global-reach-with-canadian-approval 2025-09-11T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/6cc5aa180d172090/uc-davis-health-ventures-makes-inaugural-investment-in-delix-therapeutics-non-hallucinogenic-depression-treatment 2025-09-11T09:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/b4ad5eef00718de8/targeted-antioxidants-reverse-t-cell-exhaustion-by-protecting-telomeres-in-cancer-therapy 2025-09-11T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/0ff830beef5a5b94/xingimaging-and-synusight-receive-3-84m-grant-to-advance-first-a-synuclein-pet-tracer-for-parkinson-s-disease 2025-09-11T05:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/9ef8bfce0aad0bd2/capsida-suspends-gene-therapy-trial-after-first-patient-dies-following-treatment-for-rare-stxbp1-disorder 2025-09-11T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/60d497777e6d1e9c/amgen-s-imdelltra-receives-fda-approval-and-guideline-upgrade-rocatinlimab-phase-3-data-awaited 2025-09-11T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/b71026451f6bd8ca/precision-tools-transform-breast-cancer-survivorship-care-as-patients-navigate-post-treatment-challenges 2025-09-11T05:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/6b219f502883a8ba/dewpoint-therapeutics-secures-series-d-funding-to-advance-novel-condensate-modulator-for-gastric-cancer 2025-09-11T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/338d06b591347c72/fda-launches-major-crackdown-on-misleading-pharmaceutical-advertising-under-trump-administration 2025-09-11T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/52263199e6537590/nih-study-shows-jail-based-opioid-treatment-reduces-fatal-overdoses-by-52-and-improves-post-release-outcomes 2025-09-11T01:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/9c4177eca27a6e63/sagimet-s-denifanstat-shows-significant-anti-fibrotic-benefits-in-advanced-mash-patients-at-aasld-2025 2025-09-11T01:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/a8b3e6b3b4e8bf25/neurosense-s-primec-shows-enhanced-neuroplasticity-in-alzheimer-s-patient-derived-neurons 2025-09-11T01:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/da32eb529bda496b/university-of-maine-researchers-develop-sustainable-wood-based-production-method-for-key-pharmaceutical-building-block 2025-09-11T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/f87a21d15c5a8ba2/design-therapeutics-appoints-former-gw-pharmaceuticals-ceo-justin-gover-to-board-of-directors 2025-09-11T01:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/ee276361a10c8a78/bassett-research-institute-receives-12-million-pcori-grant-to-study-kidney-effects-of-common-antibiotic-combination 2025-09-11T01:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/55b975e74e30d09c/apozeal-pharmaceuticals-secures-4-1m-investment-to-expand-generic-drug-manufacturing-in-pennsylvania 2025-09-11T01:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/5e4eac851fd3c928/centinel-spine-achieves-fda-approval-for-two-level-cervical-disc-replacement-with-record-breaking-clinical-success-rate 2025-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e98e82e00ed74d01/fibrobiologics-reports-breakthrough-in-bone-marrow-organoid-platform-for-cancer-and-immune-system-regeneration 2025-09-10T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/a32ebd944cff9e4e/lutetium-lu-177-dotatate-shows-promise-in-metastatic-bronchopulmonary-neuroendocrine-tumors 2025-09-10T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/8399b77de2003c6b/basal-cell-neoplasm-drug-pipeline-expands-with-22-companies-developing-novel-therapies 2025-09-10T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/4eb112a95c85f800/jak1-inhibitors-show-superior-antipruritic-effects-over-il-13-antibodies-in-atopic-dermatitis 2025-09-10T21:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/15f91e9f818d5681/nurexone-s-exopten-shows-promising-results-in-spinal-cord-injury-and-glaucoma-preclinical-studies 2025-09-10T21:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/988d903fcb9ff0e6/merck-abandons-ps1-billion-london-research-centre-cuts-125-uk-science-jobs 2025-09-10T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/a83deb1b5275f8f1/france-approves-compassionate-access-for-agenus-bot-bal-immunotherapy-in-refractory-mss-colorectal-cancer 2025-09-10T21:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/a8093702bea3a608/kfshrc-achieves-first-locally-manufactured-car-t-cell-treatment-in-saudi-arabia 2025-09-10T21:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/48a2c9f1563ec534/new-retinal-formulation-retaxome-shows-enhanced-tolerability-in-clinical-studies 2025-09-10T21:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/968f738c417f4831/merck-halts-u-k-research-operations-abandons-london-facility-over-nhs-drug-pricing-disputes 2025-09-10T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/0b56aad1f95acab0/truleaf-achieves-first-in-human-implantation-of-revolutionary-catheter-based-heart-valve-system 2025-09-10T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/4e4b16b1cba3639b/500000-grant-expands-phase-2-trial-of-wokvac-breast-cancer-vaccine-at-university-of-washington 2025-09-10T21:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/b44e50da3da986df/dianthus-therapeutics-soars-50-following-positive-phase-2-results-for-myasthenia-gravis-drug 2025-09-10T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/86070120744708ff/innorna-completes-phase-ii-enrollment-for-world-s-first-bivalent-rsv-mrna-vaccine 2025-09-10T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/a01937f6724feb6b/imaging-endpoints-files-patent-for-ai-enhanced-imaging-review-charter-system-to-optimize-oncology-trials 2025-09-10T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/cd32523ddb46437d/ppar-gamma-pathway-modulation-enhances-nectin4-targeted-car-t-therapy-for-bladder-cancer 2025-09-10T17:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/0f79a3a34d4afba3/exact-sciences-launches-cancerguard-multi-cancer-blood-test-for-early-detection 2025-09-10T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/7a476ac1f47673a6/sublingual-edaravone-dexborneol-tablet-shows-superior-cost-effectiveness-for-acute-ischemic-stroke-treatment 2025-09-10T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/b94363a93a8956dc/kadimastem-and-nls-pharmaceutics-clear-final-sec-hurdle-for-merger-creating-newcelx 2025-09-10T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/1bfe68d7d9cc20a9/galectin-therapeutics-belapectin-shows-49-reduction-in-liver-varices-stock-hits-52-week-high 2025-09-10T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/03a1ef711e1838b7/cuspai-raises-100-million-series-a-to-accelerate-ai-driven-materials-discovery-for-healthcare-and-sustainability 2025-09-10T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/cd33981ca79f8ba2/tepotinib-shows-high-frequency-of-adverse-events-but-manageable-safety-profile-in-met-exon-14-altered-nsclc 2025-09-10T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/bd0818d6c65974e0/symeres-acquires-dgr-pharma-to-strengthen-integrated-drug-development-services 2025-09-10T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/1e004cdc802c49d9/euda-health-signs-letter-of-intent-to-acquire-ipsc-platform-developer-go-posb-for-regenerative-medicine-expansion 2025-09-10T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/f25fd2041b6cc2f7/mednovo-doses-first-patient-in-phase-iii-trial-of-lutetium-177-radiotherapy-for-neuroendocrine-tumors 2025-09-10T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/dc1df605edb43d13/aurora-2-study-shows-no-increased-nephrotoxicity-with-voclosporin-in-lupus-nephritis-after-18-months 2025-09-10T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/26810ab7df98b46e/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer 2025-09-10T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/5ed015013dbcf4ca/dermata-therapeutics-pivots-from-prescription-to-otc-dermatology-products-following-successful-phase-3-acne-trial 2025-09-10T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/85e8849742ae0a30/pmv-pharma-s-rezatapopt-demonstrates-33-response-rate-in-phase-2-trial-for-tp53-y220c-solid-tumors 2025-09-10T17:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/ef5e306f32b713f5/orimed-pharma-launches-prsolufy-first-liquid-aripiprazole-solution-in-canada 2025-09-10T17:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/605648ca69b0ec2c/iqvia-launches-ai-powered-clinical-trial-financial-suite-to-automate-site-payments-and-budget-management 2025-09-10T17:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/f8862f315775443b/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer-prevention 2025-09-10T13:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/4f05550f27c1e6ce/celcuity-secures-500-million-credit-facility-following-positive-phase-3-data-for-gedatolisib-in-advanced-breast-cancer 2025-09-10T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/59b5eedfe2a97206/aphaia-pharma-advances-oral-glucose-based-obesity-treatment-with-second-phase-2-trial 2025-09-10T13:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/f287ef1051e65d96/cascade-bio-raises-6m-to-advance-cell-free-biocatalyst-technology-for-industrial-manufacturing 2025-09-10T13:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/3f4e3cfb6903bc50/fda-approves-obagi-saypha-magiq-injectable-hyaluronic-acid-filler-marking-waldencast-s-entry-into-us-dermal-filler-market 2025-09-10T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/60be35ea41cbbff8/diamyd-medical-secures-key-patents-for-precision-medicine-approach-to-type-1-diabetes-treatment 2025-09-10T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/4efea632aee2aefb/revelation-biosciences-gemini-shows-promise-in-phase-1b-trial-for-chronic-kidney-disease 2025-09-10T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/93034f281865491c/cutiss-raises-eur57-9m-series-c-to-advance-phase-3-trial-of-personalized-skin-graft-therapy 2025-09-10T13:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/23b769ac26ed9c6e/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-as-companies-advance-novel-treatment-approaches 2025-09-10T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e97eb0234896913/vedabio-secures-40m-series-a-and-strategic-partnership-with-siemens-healthineers-for-crispr-diagnostics-platform 2025-09-10T09:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/ec5a07dd81c5770a/fda-accepts-sobi-s-nasp-biologics-license-application-for-uncontrolled-gout-treatment 2025-09-10T09:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/1664596ee17c215b/resolution-therapeutics-strengthens-leadership-team-with-key-executive-appointments-as-rtx001-advances-in-clinical-trials 2025-09-10T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/c00cb68a372b5c05/iga-nephropathy-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-09-10T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/a186fb77f216ac7e/health-canada-approves-bylvay-for-alagille-syndrome-treatment-marking-first-dual-indication-rare-disease-therapy 2025-09-10T06:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/6e216aa21bb6151a/beckman-coulter-life-sciences-partners-with-hse-ag-to-automate-nucleic-acid-quantification-workflows 2025-09-10T06:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/2dc46b3d2c08ed1a/varian-secures-first-european-approval-for-knee-arthritis-embolization-device 2025-09-10T06:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/b80b815dcc1518d0/scenic-biotech-appoints-dr-roland-w-burli-as-chief-scientific-officer-to-advance-modifier-therapy-pipeline 2025-09-10T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/0711667785950ce2/world-s-first-koala-chlamydia-vaccine-receives-regulatory-approval-in-australia 2025-09-10T04:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/a0bffdfd9fd44b64/qiagen-receives-fda-clearance-for-qiastat-dx-rise-system-launches-globally-across-100-countries 2025-09-10T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/c7a5aac7bd3f5065/failed-als-drug-biib078-reached-target-but-failed-to-halt-disease-progression-emory-study-reveals 2025-09-10T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/5b843522f90c1762/regeneron-s-libtayo-combination-therapy-demonstrates-19-4-five-year-survival-rate-in-advanced-lung-cancer 2025-09-10T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/c4c158b695ac9fb8/paloma-2-study-confirms-efficacy-of-subcutaneous-amivantamab-in-egfr-exon-20-insertion-nsclc 2025-09-10T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/5c9b67ad61c5998a/wheeler-bio-partners-with-pharmefex-to-enhance-modularcmc-platform-for-ind-submissions 2025-09-10T01:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/0dae9335a5a67dd9/scribe-therapeutics-demonstrates-breakthrough-crispr-therapy-for-cardiovascular-disease-with-90-lp-a-reduction 2025-09-10T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/0952644f3729e844/nih-recover-tlc-launches-second-round-of-long-covid-clinical-trials-testing-glp-1-drugs-and-other-interventions 2025-09-10T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/d3dd875c5996c7be/analog-pharma-canada-launches-generic-pregnancy-nausea-treatment-in-canadian-market 2025-09-10T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/b8355d7cda2f6b58/sunobinop-shows-promising-results-in-phase-1b-trial-for-interstitial-cystitis-bladder-pain-syndrome 2025-09-10T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/267332acf7803969/dz-002-cancer-therapy-advances-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-09-10T01:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/d0d68f8f0cd3fa4d/wearable-devices-secures-patent-for-ai-powered-voice-and-gesture-control-technology 2025-09-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/16b535fb4fedf0b2/nurexone-secures-u-s-patent-for-proprietary-exosome-manufacturing-technology 2025-09-09T21:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/2b8d85dfd674b4c5/pakistan-drug-authority-orders-immediate-recall-of-contaminated-metronidazole-infusion-over-bacterial-endotoxin-contamination 2025-09-09T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/bb88886e8400f9a4/delaware-court-rules-against-novo-nordisk-in-wegovy-patent-case-highlighting-challenges-in-method-of-treatment-claims 2025-09-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/aaf3a33915856aaa/circulating-tumor-dna-monitoring-enables-personalized-immunotherapy-in-limited-stage-small-cell-lung-cancer 2025-09-09T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/bbe67134cf7eeb7d/breakwater-study-reveals-ctdna-clearance-predicts-survival-in-braf-v600e-mutant-colorectal-cancer 2025-09-09T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/ab983b18df97d20f/tspo-biomarker-shows-promise-for-early-alzheimer-s-detection-years-before-symptom-onset 2025-09-09T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/0372aebe973eb988/topcon-healthcare-invests-in-senseye-s-ai-powered-mental-health-diagnostic-platform-using-ocular-biomarkers 2025-09-09T21:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/7abe222a12bd5890/lgc-group-opens-100-million-organic-chemistry-synthesis-center-in-canada-to-expand-global-drug-discovery-support 2025-09-09T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/cf0236e735c1cbef/brief-anesthesia-shows-no-short-term-neurodevelopmental-risk-in-infants-under-2-years 2025-09-09T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/145aa62c8552807a/icer-reverses-position-on-glp-1-obesity-drugs-finds-cost-effectiveness-despite-budget-concerns 2025-09-09T21:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/3f94df5664f58226/iregene-therapeutics-raises-40m-series-b-following-fda-fast-track-designation-for-parkinson-s-cell-therapy 2025-09-09T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/19ec79afbad8653e/regeneron-s-allergen-blocking-antibodies-achieve-primary-endpoints-in-phase-iii-cat-and-birch-allergy-trials 2025-09-09T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/ff94ad2991a7825f/cpap-treatment-reduces-mortality-risk-by-26-in-adults-with-type-2-diabetes-and-sleep-apnea 2025-09-09T17:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/5d4de88e5a7d384f/rion-spins-out-intent-biologics-to-advance-exosome-based-therapies-for-inflammation-and-immunology 2025-09-09T17:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/44388fe992e55e5b/cancer-centers-pioneer-decentralized-clinical-trial-models-to-expand-patient-access-nationwide 2025-09-09T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/3949f592bf819956/bee-sting-inspired-microneedles-deliver-pain-free-drug-therapy-for-neurological-diseases 2025-09-09T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/c4cd0c2576e36ccf/nkgen-biotech-completes-16-9m-acquisition-of-nkmax-gains-control-of-nk-cell-manufacturing 2025-09-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/6e39033427f90228/immunic-secures-fifth-us-patent-for-multiple-sclerosis-drug-vidofludimus-calcium-extending-protection-through-2041 2025-09-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/d65ece4a672f122e/cho-plus-secures-u-s-patent-for-engineered-yeast-cell-technology-to-boost-protein-production 2025-09-09T17:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/6b2349f44686a7df/kytopen-and-bluewhale-bio-partner-to-accelerate-non-viral-cell-therapy-manufacturing 2025-09-09T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/d864dab419282dfb/viral-immunotherapy-can-2409-demonstrates-24-5-month-median-survival-in-checkpoint-inhibitor-resistant-nsclc 2025-09-09T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/bde66c227f8013c5/mit-researchers-develop-bottlebrush-polymer-technology-to-dramatically-increase-cancer-drug-payload-delivery 2025-09-09T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/778b36f970a57fe9/hope-biosciences-stem-cell-therapy-achieves-primary-endpoint-in-phase-2-multiple-sclerosis-trial 2025-09-09T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/db8b0c324324079a/linusbio-develops-first-hair-based-biomarker-for-als-detection-using-copper-patterns 2025-09-09T17:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/b42bcc9a29468a3a/vicero-appoints-dr-han-myint-as-chief-medical-officer-to-advance-vincobody-immunotherapy-pipeline 2025-09-09T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/663b862895e3c847/liscure-biosciences-achieves-world-s-first-fda-ndi-notification-for-hair-health-probiotic-mobiome-r 2025-09-09T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/8bd1c00dd568e9f0/oncoc4-and-biontech-advance-pivotal-phase-3-trial-of-next-generation-ctla-4-antibody-gotistobart-in-squamous-nsclc 2025-09-09T17:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/59c1daf4d9630715/boston-scientific-acquires-elutia-s-bioenvelope-business-for-88-million-fueling-breast-reconstruction-pipeline 2025-09-09T17:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/f0865b53c88d584c/insitro-and-eli-lilly-partner-to-develop-ai-powered-admet-prediction-models-for-small-molecule-drug-discovery 2025-09-09T17:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/608afeeace36dab7/xtalpi-s-ai-designed-prmt5-inhibitor-pep08-receives-clinical-trial-approvals-for-solid-tumors 2025-09-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/11195f950ebac023/ionctura-expands-roginolisib-clinical-trials-to-us-market-with-multi-cancer-strategy 2025-09-09T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/4a3b72d978905db0/cellcentric-completes-enrollment-for-inobrodib-dose-optimization-study-in-multiple-myeloma 2025-09-09T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/1d329e65f96a4a83/tempus-validates-purist-algorithm-for-personalized-pancreatic-cancer-treatment-selection-in-largest-real-world-study 2025-09-09T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/1841b2006d4e20bd/teva-s-emrusolmin-receives-fda-fast-track-designation-for-multiple-system-atrophy-treatment 2025-09-09T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5ff7098c26d4ad2/fda-grants-fast-track-designation-to-ns-229-jak1-inhibitor-for-rare-autoimmune-disease-egpa 2025-09-09T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/58d879ec27624c9e/ridge-biotechnologies-emerges-from-stealth-with-25m-seed-funding-for-ai-driven-enzyme-design-platform 2025-09-09T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/c255364e87f72e3b/real-world-study-confirms-inotuzumab-ozogamicin-efficacy-in-indian-patients-with-relapsed-refractory-b-cell-all 2025-09-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8452237ede552b64/alembic-pharmaceuticals-secures-fda-approval-for-phytonadione-injectable-emulsion-in-44-million-market 2025-09-09T13:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/613b578f94fb1fa2/pheon-therapeutics-appoints-google-ventures-dr-samuel-blackman-to-board-as-adc-programs-advance 2025-09-09T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/d647ce4810d23d6f/integra-therapeutics-raises-eur10-7-million-to-advance-ficat-gene-writing-platform-and-car-t-therapies 2025-09-09T13:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/718015d57cf5fe98/cambridge-scientists-develop-ph-responsive-artificial-cartilage-for-targeted-arthritis-drug-delivery 2025-09-09T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/d7dd092633f1f748/fda-issues-updated-guidance-for-therapeutic-protein-biosimilar-development-with-enhanced-analytical-requirements 2025-09-09T13:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/027f52a5d7b63fb9/connecta-therapeutics-advances-first-in-class-neuroplasticity-modulator-cth120-to-phase-ii-for-pediatric-fragile-x-syndrome 2025-09-09T13:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/7055d05161b05589/surgical-resection-combined-with-egfr-tki-shows-promising-results-in-metastatic-nsclc-trial 2025-09-09T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/a623416a2c27649b/eli-lilly-launches-tunelab-ai-platform-to-democratize-drug-discovery-for-biotech-companies 2025-09-09T13:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/cb752d7544be86dd/mirum-pharmaceuticals-completes-enrollment-in-phase-2b-vistas-study-for-primary-sclerosing-cholangitis-treatment 2025-09-09T13:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/18745ced02cbf13b/adcs-transform-nsclc-treatment-landscape-with-multiple-fda-approvals-and-expanding-clinical-applications 2025-09-09T10:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/14bb490caf806df5/tevogen-s-tvgn-489-t-cell-therapy-achieves-9-11-billion-valuation-following-successful-covid-19-trial 2025-09-09T09:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/5a3d89de79ff1b7b/matica-biotechnology-partners-with-cirsium-biosciences-to-advance-plant-based-aav-manufacturing-for-gene-therapy 2025-09-09T09:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/dddffc66b23c8b27/alchemab-therapeutics-initiates-phase-1-trial-of-atlx-1282-and-secures-32-million-series-a-extension 2025-09-09T09:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/a10ae0f7a7f34a23/eli-lilly-recruits-former-fda-cell-and-gene-therapy-official-rachael-anatol-to-lead-genetic-medicine-strategy 2025-09-09T09:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/04e8486f3aa5d4fa/remedium-bio-partners-with-eli-lilly-to-develop-gene-therapies-for-obesity-and-type-2-diabetes 2025-09-09T09:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/e8668c79b42d6ce0/novartis-acquires-tourmaline-bio-for-1-4-billion-to-advance-anti-inflammatory-cardiovascular-therapy 2025-09-09T09:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/6da04b42ff551685/sandoz-resolves-patent-dispute-with-regeneron-clearing-path-for-eylea-biosimilar-launch-by-2026 2025-09-09T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/fe09a922cdba7abf/sandoz-secures-patent-settlement-with-regeneron-clears-path-for-aflibercept-biosimilar-launch-by-end-of-2026 2025-09-09T09:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/6a7e8f15cbc99e25/strides-pharma-partners-with-kenox-to-expand-us-nasal-spray-portfolio 2025-09-09T09:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/764dbdc93b94bc8e/novartis-acquires-tourmaline-bio-for-1-4-billion-to-strengthen-cardiovascular-pipeline-with-pacibekitug 2025-09-09T09:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/c09b1923308802bb/synthetic-peptide-pep19-shows-promise-in-reducing-visceral-fat-and-improving-sleep-in-obese-adults 2025-09-09T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/82297bb3c86544ba/tolerance-bio-partners-with-zipcode-bio-to-develop-targeted-thymus-therapeutics-for-immune-aging 2025-09-09T06:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/3641fc28d61bd9b9/dianthus-therapeutics-closes-upsized-288-million-public-offering-to-advance-complement-therapeutics-pipeline 2025-09-09T06:45:05+00:00 hourly 0.9 https://trial.medpath.com/news/61290a0a09c6b49b/metformin-reduces-long-covid-risk-by-64-in-overweight-adults-uk-study-finds 2025-09-09T06:42:35+00:00 hourly 0.9 https://trial.medpath.com/news/cd414c78cd9b5856/photonpharma-secures-u-s-patent-for-novel-cancer-immunotherapy-using-photochemically-inactivated-tumor-cells 2025-09-09T06:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/2d35a516374dc920/pressure-enabled-drug-delivery-system-enhances-nelitolimod-efficacy-in-liver-tumors 2025-09-09T06:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/df464a81328704d3/astellas-restructures-leadership-team-with-digital-and-transformation-functions-integration 2025-09-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebbbe08036357638/amo-pharma-launches-largest-ever-clinical-trial-for-rare-heart-condition-arvc-with-gsk3b-inhibitor-amo-02 2025-09-09T04:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/07d9ffef8a769276/four-jak-inhibitors-now-enable-personalized-myelofibrosis-treatment-approaches 2025-09-09T04:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/2ef854f83fe1ab27/seladelpar-shows-promise-in-stabilizing-liver-stiffness-in-primary-biliary-cholangitis-patients 2025-09-09T02:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/cf8e8eb3bac87548/daiichi-sankyo-expands-global-research-network-with-new-san-diego-institute-and-154m-shanghai-adc-manufacturing-facility 2025-09-09T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/2904cd1ad4e1847c/sound-wave-innovation-and-sumitomo-heavy-industries-partner-to-advance-lipus-brain-device-for-alzheimer-s-treatment 2025-09-09T01:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/e88fbf3daaceecbc/immix-biopharma-secures-strategic-investment-from-goose-capital-for-al-amyloidosis-car-t-therapy 2025-09-09T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/e489db80f64d9918/biontech-bristol-myers-bispecific-antibody-achieves-76-3-response-rate-in-small-cell-lung-cancer-phase-ii-trial 2025-09-08T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/e114c6b0f3e5aade/uc-san-diego-researchers-develop-non-hormonal-hydrogel-treatment-for-menopausal-vaginal-symptoms 2025-09-08T21:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/5fdd73f3726ae928/real-world-data-shows-dora-insomnia-drugs-have-minimal-abuse-potential-compared-to-traditional-sleep-medications 2025-09-08T21:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/f1ab4dcd0a81b1fc/scotland-approves-linzagolix-for-endometriosis-treatment-expanding-access-across-uk 2025-09-08T21:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/345c4e5e18921d01/aavivo-advances-in-vivo-car-t-platform-with-pace-technology-for-precision-gene-delivery 2025-09-08T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/ca4751408d769ce5/apollo-trial-establishes-new-standard-for-high-risk-acute-promyelocytic-leukemia-treatment 2025-09-08T21:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/609cfbc67faceab9/phanes-therapeutics-doses-first-biliary-tract-cancer-patient-with-novel-bispecific-antibody-spevatamig 2025-09-08T21:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/d66686c2a6382f57/dianthus-therapeutics-claseprubart-meets-all-endpoints-in-phase-2-myasthenia-gravis-trial 2025-09-08T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/0c937891f4b0313f/pfizer-biontech-covid-booster-shows-strong-immune-response-in-late-stage-study 2025-09-08T21:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/664174b8a6ffd864/azacitidine-ruxolitinib-combination-shows-promise-for-advanced-myeloproliferative-neoplasms 2025-09-08T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/8c8d0a485df31c4b/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-extensive-stage-small-cell-lung-cancer 2025-09-08T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/de09a7f2b6e2f3f9/cs-diagnostics-submits-patent-application-for-cs-protect-hydrogel-organ-spacer-device 2025-09-08T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/9d0b840ded238b4e/fda-issues-complete-response-letter-for-saol-s-sl1009-treatment-for-rare-pediatric-mitochondrial-disease 2025-09-08T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/05c4fbe024ae3669/kbi-biopharma-partners-with-infinimmune-to-advance-human-first-antibody-manufacturing-for-atopic-dermatitis 2025-09-08T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/eb6deab3a907dfe3/beyond-air-s-neuronos-receives-fda-orphan-drug-designation-for-glioblastoma-therapy-ba-101 2025-09-08T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/cdb87dcdb3de1bd4/anktiva-reverses-lymphopenia-and-extends-survival-in-checkpoint-inhibitor-resistant-lung-cancer 2025-09-08T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/3334f9909c02b2e1/icecure-s-prosense-cryoablation-system-achieves-superior-results-in-early-stage-breast-cancer-trial 2025-09-08T17:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/adaf8ca4a7653adf/cormedix-makes-5-million-strategic-investment-in-talphera-s-phase-3-anticoagulant-program 2025-09-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/d8cf1e96e0306ea0/fda-clears-clinical-trial-for-pig-kidney-transplants-as-second-patient-achieves-dialysis-free-life 2025-09-08T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/6069708f960f3a29/researchers-develop-3d-printing-glue-gun-for-real-time-bone-graft-surgery 2025-09-08T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/178fc6f964cb0ce2/atom-therapeutics-urat1-inhibitor-lingdolinurad-meets-primary-endpoint-in-phase-2b-3-chronic-gout-trial 2025-09-08T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/51542752486c54c8/hypofractionated-radiotherapy-reduces-treatment-time-and-toxicity-while-maintaining-survival-in-limited-stage-small-cell-lung-cancer 2025-09-08T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/24621fb504dc5ccd/regeneron-s-first-in-class-allergen-blocking-antibodies-show-52-reduction-in-cat-allergy-symptoms-in-phase-3-trials 2025-09-08T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/3cd0acd838f92c2e/phase-3-ea5181-trial-shows-no-survival-benefit-for-concurrent-durvalumab-with-chemoradiotherapy-in-stage-iii-nsclc 2025-09-08T13:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/711ce1e0c8965aa4/charm-therapeutics-appoints-dr-erkut-bahceci-as-cmo-to-lead-next-generation-menin-inhibitor-development 2025-09-08T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/f0e00ba9cccb322f/tigulixostat-shows-superior-efficacy-over-febuxostat-in-phase-2-gout-trial 2025-09-08T13:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/2446632b3e82d5ff/stanford-university-receives-double-digit-million-nih-grant-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-09-08T13:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/6aaacbc492f75adb/locate-bio-receives-fda-ide-approval-to-expand-restore-clinical-study-of-ldgraft-bone-graft-substitute-to-us 2025-09-08T13:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/bda1b524be02fa4a/dea-licensing-contradictions-block-fda-approved-cannabis-research-while-va-seeks-foreign-imports 2025-09-08T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/7c77a7201530473a/nrg-therapeutics-raises-67-million-to-advance-novel-mitochondrial-targeting-therapy-for-parkinson-s-and-als 2025-09-08T13:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/f21b77e6094e2ba0/u-s-pointer-trial-demonstrates-lifestyle-interventions-can-prevent-cognitive-decline-in-diverse-populations 2025-09-08T10:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/9ceba2bf0ef68062/sirnaomics-secures-hkd-138-million-strategic-investment-from-bloomage-biotech-for-rnai-therapeutics-development 2025-09-08T09:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/f1f11129e5417048/toolgen-files-patent-infringement-lawsuit-against-lonza-over-crispr-technology-used-in-casgevy-production 2025-09-08T09:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/c32223fa7ff9ae93/servier-acquires-ker-0193-for-450m-to-target-fragile-x-syndrome-marking-first-neurology-asset 2025-09-08T09:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/77133e25f960f876/innocare-s-btk-inhibitor-orelabrutinib-gains-singapore-approval-for-relapsed-refractory-marginal-zone-lymphoma 2025-09-08T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/09b4300009acaf72/fda-launches-fast-track-review-program-for-nicotine-pouches-under-trump-administration-pressure 2025-09-08T09:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/5a85ed2fdc7024fa/mankind-pharma-receives-cdsco-approval-for-phase-1-trial-of-jak-inhibitor-mkp11093-for-autoimmune-disorders 2025-09-08T09:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/ff494c2e118663b3/a2-bio-to-present-early-clinical-data-from-logic-gated-car-t-therapy-trials-at-sitc-2025 2025-09-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f0dacdb5e164432/epigenic-therapeutics-secures-60-million-series-b-to-advance-epigenetic-therapies-for-hepatitis-b-and-cholesterol 2025-09-08T06:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/ace288d044a13b5b/new-zealand-passes-medicines-amendment-act-to-accelerate-drug-approvals-through-international-recognition 2025-09-08T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/2751a948aa1a6a7f/aumolertinib-plus-anlotinib-shows-promise-for-untreated-egfr-mutant-nsclc-with-cns-metastases 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/82bb53c2b773999c/aspirin-therapy-shows-no-significant-benefit-for-chronic-rhinosinusitis-with-nasal-polyps-in-randomized-trial 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c05c62a67d62508c/celltrion-receives-fda-approval-for-eydenzelt-first-aflibercept-biosimilar-for-retinal-diseases 2025-09-07T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/db837c2c34b795bd/precigen-s-papzimeos-becomes-first-fda-approved-treatment-for-rare-respiratory-disease 2025-09-07T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/568c59e10e0a3b93/biotech-stocks-surge-following-acip-rsv-vaccine-recommendations-and-gilead-pipeline-updates 2025-09-07T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/f7eda2bdbc27639e/junshi-biosciences-il-17a-inhibitor-js005-meets-primary-endpoints-in-phase-3-psoriasis-trial 2025-09-07T17:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/9212ca49bd3a276d/abbv-706-shows-promising-58-response-rate-in-relapsed-small-cell-lung-cancer-phase-i-trial 2025-09-07T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/bc3a658e9c2531a5/adjuvant-crizotinib-fails-to-improve-disease-free-survival-in-early-stage-alk-positive-nsclc 2025-09-07T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/ff6a0ddf75954f05/summit-therapeutics-ivonescimab-shows-regional-efficacy-disparities-in-phase-iii-lung-cancer-trial 2025-09-07T13:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/688a1c29d5eac856/genesight-pharmacogenomic-test-demonstrates-significant-clinical-benefits-for-major-depressive-disorder-treatment 2025-09-07T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/78d3365085248405/sanofi-s-amlitelimab-shows-significant-efficacy-in-phase-3-atopic-dermatitis-trial 2025-09-07T02:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/9ec3105472b71af4/adagene-s-masked-anti-ctla-4-therapy-adg126-shows-30-response-rate-in-treatment-resistant-colorectal-cancer 2025-09-07T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/17b4a7e97782cc82/checkmate-77t-trial-shows-perioperative-nivolumab-preserves-quality-of-life-in-resectable-nsclc 2025-09-07T01:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/3d53450f521a5fd2/fda-issues-warning-to-amneal-pharmaceuticals-over-contaminated-iv-bags-in-sterile-injectable-production 2025-09-07T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/795c11e061315703/ai-lung-cancer-risk-model-sybil-validated-in-predominantly-black-patient-population 2025-09-07T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/1dba78746bbb4b2d/theratechnologies-launches-egrifta-wr-first-weekly-formulation-for-hiv-associated-lipodystrophy 2025-09-07T01:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/c21702913b746a0d/h2-global-group-receives-european-regulatory-approval-for-first-hydrogen-inhalation-therapy-trial-in-alzheimer-s-disease 2025-09-06T21:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/75de88fc0c057f54/sprintray-acquires-envisiontec-dental-portfolio-following-desktop-metal-bankruptcy 2025-09-06T21:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/40838a15696edcf8/nuvation-bio-surges-14-9-on-analyst-upgrades-and-oncology-pipeline-progress 2025-09-06T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/64bac7a2cfb4c1a2/md-anderson-researchers-advance-cancer-treatment-with-novel-pan-kras-inhibitor-and-precision-therapies 2025-09-06T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/a777626e22e5d850/regeneron-s-cemdisiran-shows-positive-phase-3-results-driving-investment-interest-despite-mixed-market-performance 2025-09-06T17:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/5dbbea023c36912c/ultrasound-ai-secures-patent-for-ai-driven-clinical-value-determination-from-medical-images 2025-09-06T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/8963dc4e356bd16d/hinge-bio-strengthens-leadership-team-and-publishes-promising-data-for-novel-lupus-treatment-hb2198 2025-09-06T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/18d7d603fcdffad9/oecd-approves-toxys-toxtracker-for-global-test-guideline-programme-advancing-animal-free-genotoxicity-testing 2025-09-06T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/3442a872bbb1a4fc/biomarin-reports-positive-phase-3-results-for-palynziq-in-adolescent-pku-patients 2025-09-06T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/bc77621dd4497143/lila-biologics-partners-with-eli-lilly-for-ai-driven-radioligand-therapy-development 2025-09-06T09:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/6cbf5c59390769ea/cognivia-s-covariate-adjustment-method-improves-clinical-trial-precision-by-23-4-for-subjective-endpoints 2025-09-06T05:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/228e33b1eb0d11d1/fda-expands-vonvendi-approval-to-include-pediatric-von-willebrand-disease-patients 2025-09-06T05:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/52e24f4d919b8cc6/advanced-digital-pathology-methods-transform-trop2-biomarker-assessment-in-nsclc 2025-09-06T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/7e1be550b8feb346/legend-biotech-explores-dual-listing-strategy-to-accelerate-car-t-therapy-expansion 2025-09-06T01:13:14+00:00 hourly 0.9 https://trial.medpath.com/news/96f8ca7b72e10088/dupilumab-and-remibrutinib-emerge-as-new-treatment-options-for-chronic-spontaneous-urticaria 2025-09-06T01:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/d965705780d36e1e/fda-implements-import-alert-to-combat-unsafe-glp-1-drug-ingredient-imports-amid-obesity-treatment-shortage 2025-09-06T01:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/34b6745ee0aebae1/dbv-technologies-launches-150m-atm-program-to-fund-viaskin-peanut-patch-bla-submissions 2025-09-06T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/c473fdfa93cbbaa8/dbv-technologies-establishes-150-million-at-the-market-program-to-fund-viaskin-peanut-patch-development 2025-09-06T01:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/084ac5c75f82a57d/augurex-presents-novel-14-3-3eta-biomarker-data-for-axial-spondyloarthritis-diagnosis-at-acr-convergence-2025 2025-09-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6cc046c3b4c7f08e/curapath-and-cayman-chemical-partner-to-expand-global-access-to-peg-free-lipids-for-next-generation-lnp-therapies 2025-09-05T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/135d11c9dcec6e33/bevacizumab-erlotinib-combination-shows-remarkable-72-response-rate-in-rare-hlrcc-associated-kidney-cancer 2025-09-05T21:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/45baca73bbdbe7d6/md-anderson-and-phoenix-senolytix-forge-strategic-cross-licensing-agreement-to-advance-injectable-safety-switch-technology-for-cell-and-gene-therapies 2025-09-05T21:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/0914c6d2e03ab99d/hengrui-licenses-heart-disease-drug-hrs-1893-to-braveheart-bio-for-65m-upfront-potential-1b-total 2025-09-05T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/cf9b54458e3ff77a/stanford-researchers-develop-novel-enpp1-inhibitor-stf-1623-to-transform-cold-tumors-into-immunologically-active-targets 2025-09-05T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/6d59fc412194ed19/algernon-health-secures-500k-investment-and-equipment-deal-to-launch-brain-specific-pet-imaging-network 2025-09-05T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/f52df66c8a985c13/gelteq-initiates-preclinical-trial-for-novel-gel-based-antihistamine-targeting-12b-market 2025-09-05T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/dedffee1d522e609/federal-court-rules-on-patent-damages-timeline-in-mallinckrodt-airgas-nitric-oxide-therapy-dispute 2025-09-05T21:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/addc0d75b4c8fe22/florida-cancer-specialists-presents-real-world-evidence-studies-on-blood-cancers-at-soho-2025 2025-09-05T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/ba031d115f55ace2/curatis-secures-chf-5-million-distribution-deal-with-phoenix-labs-for-pain-management-and-urology-products 2025-09-05T17:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/231380e2cb378e0c/mercy-bioanalytics-raises-59-million-series-b-to-commercialize-breakthrough-ovarian-cancer-screening-technology 2025-09-05T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/cb83fa922edf37b1/who-adds-glp-1-diabetes-drugs-to-essential-medicines-list-excludes-weight-loss-indication 2025-09-05T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/5cb84af44c9b1414/aptar-pharma-partners-with-dianosic-to-develop-novel-bioresorbable-intranasal-drug-delivery-platform 2025-09-05T17:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/fc84178e268d56e4/miwendo-solutions-secures-eur1-2-million-to-develop-ai-powered-colonoscopy-device-for-real-time-polyp-characterization 2025-09-05T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/332c052e619e12d3/uniqure-s-amt-191-gene-therapy-shows-sustained-enzyme-activity-and-ert-discontinuation-in-fabry-disease-phase-i-iia-trial 2025-09-05T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/afae242c3e22ce15/ema-safety-committee-initiates-review-of-levamisole-following-fatal-leukoencephalopathy-case 2025-09-05T17:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/a3cfd72f4b46988d/hutchmed-presents-clinical-data-for-multiple-cancer-therapies-at-major-oncology-conferences 2025-09-05T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/ed0363ec69037097/braveheart-bio-raises-185m-series-a-to-advance-hypertrophic-cardiomyopathy-drug-licensed-from-hengrui 2025-09-05T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/7d2bfe3f5e9527e1/huadong-medicine-s-ror1-targeting-adc-hdm2005-shows-promising-phase-i-results-in-relapsed-lymphomas 2025-09-05T17:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/53568b90099720fe/avadel-presents-new-lumryz-data-at-world-sleep-2025-demonstrating-real-world-efficacy-in-narcolepsy-treatment 2025-09-05T17:13:17+00:00 hourly 0.9 https://trial.medpath.com/news/14d31dc654cc2b5a/ronovo-surgical-secures-67m-series-d-led-by-johnson-johnson-advances-carina-robotic-platform-commercialization 2025-09-05T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/db1ba4e07efc12fa/case-western-reserve-university-launches-9-9m-clinical-trial-for-touch-sensing-prosthetic-arms 2025-09-05T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/c0bfe74245a1f27d/gel4med-s-g4derm-plus-shows-rapid-healing-in-complex-diabetic-foot-ulcers-with-novel-biomimetic-matrix-technology 2025-09-05T17:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/b736eaa577d8fe5c/idorsia-launches-impact-htn-initiative-with-stanford-and-duke-to-transform-difficult-to-control-hypertension-care 2025-09-05T17:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/0a9fae42e1b115fd/ai-platform-connects-nearly-300-duchenne-patients-to-clinical-trials-and-expanded-access-programs 2025-09-05T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/c79257530eb4f274/university-hospitals-receives-3-5m-gift-to-triple-cancer-clinical-trials-capacity-by-2030 2025-09-05T16:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/478e0ba1873a27f5/zydus-lifesciences-secures-two-strategic-partnerships-for-novel-505-b-2-oncology-products-in-us-market 2025-09-05T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/98312818ade97247/scynexis-presents-promising-data-on-scy-247-against-drug-resistant-fungal-infections-at-timm-12-congress 2025-09-05T13:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/4ed381a03cb909fb/myriad-s-precise-mrd-test-shows-promise-in-detecting-circulating-tumor-dna-in-oligometastatic-renal-cell-carcinoma 2025-09-05T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/d3aea0c8481fb219/biosecure-act-returns-to-congressional-agenda-with-revised-amendment-targeting-chinese-biotechnology-companies 2025-09-05T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/05974285db622496/sophia-genetics-partners-with-belgium-s-jessa-ziekenhuis-to-advance-precision-oncology-through-ai-driven-genomic-platform 2025-09-05T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/c2efc7671f754fe6/catalyst-oncology-enables-accelerated-fda-approval-for-first-in-class-ovarian-cancer-therapy 2025-09-05T13:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/39549132c41ded91/glenmark-initiates-global-phase-3-trial-for-subcutaneous-pd-l1-inhibitor-envafolimab-in-stage-iii-lung-cancer 2025-09-05T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/7238b8562ef8d223/real-world-data-shows-bispecific-antibodies-deliver-clinical-trial-level-efficacy-in-broader-multiple-myeloma-patient-populations 2025-09-05T10:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/20816ee184e8860a/hopehealth-launches-first-clinical-trial-site-for-bristol-myers-squibb-s-lupus-drug-deucravacitinib 2025-09-05T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/1726160c91d0e5d0/fda-s-project-optimus-drives-27-surge-in-bayesian-trial-designs-transforming-early-phase-cancer-drug-development 2025-09-05T09:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/8a06e866c4057e7c/indaptus-therapeutics-reports-partial-response-with-decoy20-in-urothelial-cancer-patient 2025-09-05T06:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/df723b888c4d6af9/tenon-medical-s-catamaran-si-joint-fusion-system-shows-83-fusion-rate-and-significant-pain-reduction-at-12-months 2025-09-05T06:44:46+00:00 hourly 0.9 https://trial.medpath.com/news/842a3f40d6a597d4/silexion-therapeutics-partners-with-ams-for-phase-2-3-trials-of-kras-targeting-sirna-therapy-sil204 2025-09-05T06:44:33+00:00 hourly 0.9 https://trial.medpath.com/news/6a4ae1e4a93db444/rybrevant-plus-lazcluze-demonstrates-superior-survival-in-first-line-egfr-mutated-nsclc 2025-09-05T06:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/023c352d6d0dc6fc/predictive-biomarkers-guide-ruxolitinib-treatment-optimization-in-myelofibrosis-after-15-years-of-clinical-use 2025-09-05T03:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/19156df179b0259b/cancer-nutrition-expert-outlines-dietary-strategies-to-combat-treatment-side-effects-and-support-long-term-survivorship 2025-09-05T03:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/95e73d762d87be1e/novel-gcgr-glp-1r-dual-agonist-tb001-shows-promise-for-treating-kidney-fibrosis 2025-09-05T03:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/e11051c10b2d1079/glycolytic-reprogramming-emerges-as-key-therapeutic-target-in-gastric-cancer 2025-09-05T02:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/1692219a5c8bbb4a/evernorth-health-services-makes-3-5-billion-investment-in-shields-health-solutions-to-expand-specialty-pharmacy-network 2025-09-05T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/7a1d87665e6e28be/real-world-study-launches-to-evaluate-dietary-supplements-for-cognitive-function-and-energy 2025-09-05T01:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/ed20a2d713c44027/lpoxy-therapeutics-secures-28m-series-a-to-launch-pivotal-trial-for-novel-c-difficile-prevention-therapy 2025-09-05T01:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/d39b83083b3a271b/purple-biotech-raises-6-million-in-public-offering-to-advance-novel-cancer-immunotherapy-pipeline 2025-09-05T00:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/66e60abcd4de7dbe/atlas-venture-raises-400m-opportunity-fund-to-support-biotech-portfolio-companies 2025-09-05T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/a9f195ad9c066e6f/octave-bioscience-secures-35-6m-series-c-funding-to-advance-multiple-sclerosis-precision-testing-platform 2025-09-05T00:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/b04a41df8af2c965/baylor-college-of-medicine-partners-with-site-tx-to-advance-immune-targeted-small-molecule-drug-discovery 2025-09-05T00:56:39+00:00 hourly 0.9 https://trial.medpath.com/news/4922ed983187a278/4dmedical-receives-fda-clearance-for-revolutionary-ct-vq-lung-imaging-software 2025-09-05T00:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/3065fb268b7c6dc8/cls-receives-fda-clearance-to-expand-clearpoint-prism-neuro-laser-therapy-system-to-1-5t-mri-doubling-u-s-market-access 2025-09-05T00:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/abf082347567a997/phage-therapy-advances-in-environmental-applications-show-promise-for-antimicrobial-resistance-control 2025-09-05T00:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/607f45856b9c2158/inhaled-il-15-immunotherapy-shows-promise-in-veterinary-cancer-trial-with-delayed-response-pattern 2025-09-05T00:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f13615f852d239f/boomerang-medical-secures-20m-series-b-to-advance-first-pivotal-neuromodulation-trial-for-ulcerative-colitis 2025-09-04T23:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/62aae2e717aac304/novo-nordisk-expands-manufacturing-footprint-in-north-carolina-despite-global-workforce-reduction 2025-09-04T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/205c9e7414924c9b/medtronic-s-hugo-robotic-surgery-system-achieves-100-success-rate-in-first-u-s-hernia-repair-study 2025-09-04T23:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/022a2a20a1ec27b1/predictive-oncology-partners-with-every-cure-to-accelerate-ai-driven-drug-repurposing-for-cancer-treatment 2025-09-04T20:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/20c7ca55a11a3897/ketryx-secures-39m-series-b-to-accelerate-ai-powered-compliance-platform-for-life-sciences 2025-09-04T20:44:56+00:00 hourly 0.9 https://trial.medpath.com/news/d281d8e955d89f57/sugar-coated-nanoparticles-show-promise-for-triple-negative-breast-cancer-treatment 2025-09-04T20:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/df29addd39781c7c/black-diamond-therapeutics-completes-enrollment-in-phase-ii-study-of-egfr-inhibitor-silevertinib-for-nsclc 2025-09-04T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/b9f60763b7056f7b/methotrexate-shows-cardiovascular-benefits-beyond-arthritis-treatment-in-new-study 2025-09-04T20:43:51+00:00 hourly 0.9 https://trial.medpath.com/news/37da5afeefda4895/rapafusyn-pharmaceuticals-secures-44-million-series-a-to-advance-non-degrading-molecular-glue-platform 2025-09-04T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/news/3ffd0cdc448a75d1/bluejay-therapeutics-initiates-phase-3-azure-2-trial-comparing-brelovitug-to-hepcludex-for-chronic-hepatitis-d 2025-09-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/9f75e1d5b87fc57c/senseonics-to-take-over-eversense-365-cgm-commercialization-from-ascensia-in-strategic-transition 2025-09-04T17:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/ae23cedfe855cd77/illumina-launches-protein-prep-assay-to-accelerate-drug-discovery-through-large-scale-proteomics 2025-09-04T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/7dcac98517e78704/atelerix-partners-with-rodon-global-to-revolutionize-biomedical-cold-chain-logistics-with-cryo-free-technology 2025-09-04T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/edea4f86e520f03c/vyome-s-vt-1953-demonstrates-significant-efficacy-in-phase-2-trial-for-malignant-fungating-wounds 2025-09-04T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/653921f22a50d4e8/kadimastem-secures-hong-kong-patent-for-isletrx-stem-cell-diabetes-therapy 2025-09-04T17:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/aa55aa19356f0484/euda-secures-distribution-rights-for-t-cell-immunotherapy-in-malaysia-at-8000-per-treatment 2025-09-04T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/a773c0e459ceeffe/fda-accepts-ind-application-for-biib142-first-irak4-degrader-to-enter-clinical-development-for-autoimmune-diseases 2025-09-04T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/7d8c3a7be2a72188/a-race-against-blindness-awards-1-million-to-advance-axv-101-gene-therapy-for-childhood-blindness 2025-09-04T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/27deca07c71d78de/eisai-presents-phase-ib-data-on-novel-orexin-agonist-e2086-for-narcolepsy-at-world-sleep-2025 2025-09-04T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/0d66d189eedb9c51/atara-biotherapeutics-appoints-new-board-chair-as-company-streamlines-operations-ahead-of-fda-decision 2025-09-04T17:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/d134c725204c026a/theracryf-advances-orexin-1-receptor-antagonist-for-addiction-treatment-with-korean-patent-grant-and-manufacturing-milestones 2025-09-04T17:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/f2a4482e516f015e/enveda-biosciences-raises-150m-series-d-to-advance-ai-driven-drug-discovery-platform 2025-09-04T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/a8ed1aa01fb37373/orbital-therapeutics-appoints-adam-raff-as-senior-vp-to-advance-rna-medicine-platform-toward-clinical-trials 2025-09-04T17:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/f585fc8ed8acc748/syantra-launches-immuno-oncology-therapeutic-division-to-reverse-cancer-related-immune-cell-corruption 2025-09-04T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/3c7453157d4a186d/revalia-bio-secures-14-5m-to-revolutionize-drug-development-with-human-organ-testing-platform 2025-09-04T17:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/0cd6030058ddf261/neurosense-therapeutics-secures-500000-bridge-financing-at-40-premium-ahead-of-key-als-drug-milestones 2025-09-04T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/cb9141a3a0b577d9/neuphoria-therapeutics-completes-phase-3-enrollment-for-bnc-210-social-anxiety-disorder-treatment 2025-09-04T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/3d4e5dbce9d3b005/accro-bioscience-to-present-positive-phase-ii-results-for-ac-201-tyk2-jak1-inhibitor-in-plaque-psoriasis-at-eadv-congress 2025-09-04T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/5b4eccbfd74689a5/lambdavision-secures-7m-seed-funding-to-advance-space-manufactured-artificial-retina-for-blindness-treatment 2025-09-04T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/d739bcdf4807a05a/al-s-pharma-reports-positive-phase-2-results-for-ap-101-in-als-treatment 2025-09-04T17:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/32bbb05c1c632043/science-37-and-catalent-partner-to-transform-clinical-trial-access-through-direct-to-patient-drug-delivery 2025-09-04T17:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/76802068efd440d5/onco3r-therapeutics-receives-regulatory-approval-for-first-in-human-trial-of-novel-sik3-inhibitor-o3r-5671 2025-09-04T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/c072ecbf720e601e/zydus-and-synthon-partner-to-launch-generic-multiple-sclerosis-drug-in-637-million-us-market 2025-09-04T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/50ca55b69392299f/new-real-time-imaging-method-advances-therapeutic-antibody-immunogenicity-risk-assessment 2025-09-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f8f9e61e4a0990ab/johns-hopkins-develops-urine-based-biomarker-panel-for-prostate-cancer-detection-with-91-accuracy 2025-09-04T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/dd9041de55ded067/northwestern-university-develops-novel-nanostructure-to-triple-crispr-gene-editing-efficiency 2025-09-04T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/906c4c316de46480/arecor-receives-fda-approval-for-phase-2-trial-of-ultra-concentrated-insulin-at278-in-automated-delivery-systems 2025-09-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/21f4073037b91128/aspen-pharmacare-to-launch-generic-weight-loss-drugs-at-half-the-price-of-ozempic-and-wegovy 2025-09-04T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/12fc3c2ced895667/sanofi-shares-plummet-10-as-amlitelimab-phase-iii-data-falls-short-of-dupixent-expectations 2025-09-04T13:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/730019587a7c1a95/mrm-health-secures-eur55-million-series-b-to-advance-microbiome-based-therapeutics-for-inflammatory-diseases 2025-09-04T13:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/56bea3ded90b91ec/multiomic-health-partners-with-serbia-s-bio4-campus-to-develop-ai-driven-precision-medicine-for-cardio-renal-metabolic-diseases 2025-09-04T13:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/a31e8587eda5f805/shield-therapeutics-accrufer-receives-fda-priority-review-for-pediatric-iron-deficiency-anemia 2025-09-04T13:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/b9049de09a9fc050/walden-biosciences-engages-former-fda-director-to-advance-wal0921-phase-2-trial-in-rare-kidney-diseases 2025-09-04T13:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/0a59792f36a56f8b/sentec-receives-fda-clearance-for-first-eit-system-approved-for-premature-infants-in-the-united-states 2025-09-04T13:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/4c5be31614be8372/semaglutide-shows-promise-in-reducing-cocaine-addiction-in-preclinical-study 2025-09-04T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/b4ca32669ea9f430/perspective-therapeutics-names-joel-sendek-as-cfo-to-advance-alpha-radiopharmaceutical-programs 2025-09-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c7d1b718791441e/west-coast-states-form-health-alliance-to-counter-federal-cdc-changes-and-maintain-science-based-vaccine-guidance 2025-09-04T06:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/4ee89b76aed90076/multiple-myeloma-survival-nearly-doubles-over-15-years-despite-remaining-incurable 2025-09-04T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/1f30f27cb1c93c1c/reveal-healthtech-secures-7-2m-series-a-to-advance-ai-driven-healthcare-solutions 2025-09-04T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/4ac97484b575a665/gilead-sciences-breaks-ground-on-32-billion-ai-enabled-biologics-development-center 2025-09-04T01:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/fae9732532d9c664/radiance-biopharma-secures-exclusive-license-for-first-in-class-bispecific-adc-targeting-c-met-and-egfr 2025-09-04T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/e610d3e85b7a9b26/mytos-launches-automated-cdmo-to-scale-stem-cell-therapy-manufacturing 2025-09-04T01:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/8fa4c7388701a96b/avadel-pharmaceuticals-acquires-exclusive-global-rights-to-valiloxybate-for-sleep-disorders 2025-09-04T01:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/58563fe1586b7122/single-dose-benzathine-penicillin-g-proves-as-effective-as-three-dose-regimen-for-early-syphilis-treatment 2025-09-04T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/202de3a94098be81/biohaven-prepares-for-potential-first-in-class-spinocerebellar-ataxia-drug-launch-as-fda-decision-looms 2025-09-04T01:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/08794858a3b4bc2d/vaxiion-therapeutics-advances-vax014-bacterial-minicell-therapy-to-phase-1b-combination-study 2025-09-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c30853b23a235361/ge-healthcare-receives-fda-clearance-for-revolution-vibe-ct-system-targeting-complex-cardiac-imaging 2025-09-03T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/80dfb43fc04d5b40/immunovant-s-batoclimab-shows-sustained-remission-in-graves-disease-patients-six-months-after-treatment 2025-09-03T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/1e4fdab4e6833185/gifthealth-acquires-occam-health-services-to-create-digital-pharmacy-platform-for-enhanced-patient-access 2025-09-03T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/78db716f937a23b3/artelo-biosciences-reports-promising-phase-2-results-for-art27-13-in-cancer-cachexia-treatment 2025-09-03T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/1acbde84dad25d58/university-of-utah-researchers-discover-papb-enzyme-for-enhanced-peptide-drug-development 2025-09-03T21:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/6f66f03dd4906692/bluewhale-bio-doses-first-patient-with-novel-cell-derived-nanoparticle-technology-for-car-t-manufacturing 2025-09-03T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/b5a936747885f1f4/gd2-directed-car-t-cell-therapy-shows-promise-in-pediatric-brain-cancer-with-complete-response-in-one-patient 2025-09-03T21:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/8b02f31fd92272e6/wave-life-sciences-wve-006-demonstrates-durable-aat-protein-production-in-alpha-1-antitrypsin-deficiency-trial 2025-09-03T21:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/715fa045b7df234c/merck-kgaa-appoints-david-weinreich-as-global-head-of-r-d-to-revitalize-healthcare-pipeline 2025-09-03T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/e366392a193d99cb/acute-liver-failure-pipeline-shows-promise-with-5-therapies-in-development-despite-recent-setbacks 2025-09-03T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/ed714d1ce89908c0/corstasis-therapeutics-secures-patent-for-subcutaneous-bumetanide-formulations-ahead-of-enbumyst-pdufa-date 2025-09-03T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/75216bc7470f1d87/ctc-guided-egfr-inhibitor-therapy-achieves-14-month-response-in-metastatic-hepatocellular-carcinoma 2025-09-03T21:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/2004ed099739d60b/pharmala-establishes-australian-subsidiary-to-advance-mdma-clinical-research-and-development 2025-09-03T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/831ef6e1849198e2/wave-life-sciences-rna-editing-therapy-shows-therapeutic-promise-in-alpha-1-antitrypsin-deficiency-despite-mixed-investor-reception 2025-09-03T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/2976181ae04853d1/modified-car-inkt-therapy-achieves-complete-remission-in-high-risk-childhood-leukemia-mouse-models 2025-09-03T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/b340830abcfede82/upc-court-of-appeal-grants-first-pharmaceutical-preliminary-injunction-setting-new-standard-for-generic-drug-market-entry 2025-09-03T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/1ab379dd5a759646/charles-river-laboratories-integrates-akadeum-s-microbubble-technology-into-cell-therapy-manufacturing-platform 2025-09-03T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/29438b7fb54ab480/ogrd-alliance-announces-plpc-db-non-cellular-oncology-immunotherapy-platform-for-global-acquisition 2025-09-03T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/246b75872d55ac20/de-escalated-radiation-therapy-reduces-toxicity-while-maintaining-cure-rates-in-hpv-positive-oropharyngeal-cancer 2025-09-03T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/413c00272664e0f5/kura-oncology-showcases-preclinical-data-for-next-generation-fti-ko-2806-in-combination-therapies 2025-09-03T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/e7110bad118d8b8b/parabilis-medicines-appoints-fawzi-benzaghou-as-chief-medical-officer-to-advance-undruggable-cancer-targets 2025-09-03T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/b8cc48ec7d9f1f4b/xortx-therapeutics-initiates-ind-preparation-for-xorlotm-gout-treatment-following-fda-guidance 2025-09-03T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/0cd0311398b52d1a/precigen-secures-125-million-credit-facility-to-advance-papzimeos-commercialization 2025-09-03T17:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/8f611ca2942ecde4/andelyn-biosciences-partners-with-tern-therapeutics-for-late-stage-manufacturing-of-cln2-batten-disease-gene-therapy 2025-09-03T17:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/3bbde92b7f11959a/ori-biotech-s-iro-platform-becomes-one-of-first-technologies-to-receive-fda-advanced-manufacturing-technology-designation 2025-09-03T17:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/7fcae1d01b57bfa6/strategic-partnerships-transform-gene-therapy-manufacturing-for-rare-diseases-as-market-reaches-11-4-billion 2025-09-03T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/555a94d849deaa65/savara-reports-50-increase-in-autoimmune-pap-patient-population-plans-december-2025-fda-resubmission-for-molbreevi 2025-09-03T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/23cbe6fb4b7b41a6/lantern-pharma-receives-fda-guidance-for-pediatric-cns-cancer-trial-targeting-atrt 2025-09-03T17:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/3da671e64c671d18/splisense-achieves-first-positive-phase-2-results-for-inhaled-antisense-therapy-in-cystic-fibrosis 2025-09-03T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/991b4308e7d9eaed/novartis-secures-5-2-billion-licensing-deal-with-china-s-argo-for-rnai-cardiovascular-therapies 2025-09-03T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/6cdf0ee693356f7c/treeline-biosciences-initiates-three-phase-1-trials-targeting-bcl6-kras-and-ezh2-with-1-1b-in-total-funding 2025-09-03T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/36ea9bd71cf73909/fda-vaccine-advisory-panel-loses-prominent-expert-paul-offit-amid-kennedy-administration-changes 2025-09-03T17:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/3c2d4b00f37c15af/chinese-pharmaceutical-companies-pivot-from-weight-loss-drug-compounding-to-generic-development-as-fda-restrictions-tighten 2025-09-03T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/3e16c9da69e545f0/argo-biopharma-and-novartis-expand-partnership-with-5-2-billion-cardiovascular-sirna-deal 2025-09-03T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/1510090f7317c419/arcascience-secures-7m-to-accelerate-ai-driven-drug-safety-evaluation-platform 2025-09-03T13:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/d63ea8fbac9cc774/resolution-therapeutics-doses-first-patient-with-engineered-macrophage-therapy-for-end-stage-liver-disease 2025-09-03T13:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/2b6235b66981079f/ideaya-biosciences-submits-ind-for-ide892-prmt5-inhibitor-targeting-mtap-deleted-lung-cancer 2025-09-03T13:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/0474b96f72b3052e/nucana-to-present-preclinical-data-on-nuc-7738-and-pd-1-inhibitor-combination-at-esmo-2025 2025-09-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/77efe6c6909e9c4e/microbiotix-secures-krw-20-billion-series-b-to-launch-korea-s-first-bacteriophage-clinical-trial 2025-09-03T11:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c4c2943dcdf8477/alpha-tau-initiates-first-u-s-patient-treatment-in-pancreatic-cancer-trial-combining-alpha-dart-with-chemotherapy 2025-09-03T09:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/a04882fc130cfc6b/bostongene-s-ai-model-identifies-five-novel-subtypes-to-predict-immunotherapy-response-in-kidney-cancer 2025-09-03T06:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/6c912d1c4b63be5e/mainz-biomed-launches-coloalert-colorectal-cancer-screening-test-in-switzerland-following-regulatory-approval 2025-09-03T06:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/e36ff7f88d0a423a/cml-treatment-revolution-from-deadly-disease-to-treatment-free-remission-in-25-years 2025-09-03T02:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/ccc86a683dd03741/zeaxanthin-supplement-shows-promise-in-enhancing-cancer-immunotherapy-effectiveness 2025-09-03T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/6d9aec8ac0584459/medtronic-gains-japanese-approval-for-symplicity-spyral-renal-denervation-system-to-treat-resistant-hypertension 2025-09-03T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/5ce319f0b5623228/aptamer-and-invizius-partner-to-develop-next-generation-complement-system-therapies-using-synthetic-binders 2025-09-03T01:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/d24d39b9a788f844/cognition-therapeutics-secures-30-million-to-advance-alzheimer-s-drug-zervimesine-into-phase-3-development 2025-09-03T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/2a33faaec5aa6587/new-found-gold-confirms-high-recovery-rates-in-phase-iii-metallurgical-testing-at-queensway-gold-project 2025-09-03T01:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/44dfe31a9384412f/indian-scientists-develop-novel-organoselenium-compound-showing-promise-against-triple-negative-breast-cancer 2025-09-03T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/6658ac0ea2f92ce8/covid-19-infection-linked-to-49-higher-risk-of-depression-and-anxiety-in-school-age-children 2025-09-03T01:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/9ec62f7ee373eb97/nanoparticle-vaccines-show-promise-against-hpv-related-cancers-in-preclinical-studies 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5583e35d5ecabe9c/vcu-massey-and-md-anderson-researchers-launch-7-3m-clinical-trial-targeting-cancer-stem-cells-in-metastatic-triple-negative-breast-cancer 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6e92a4e5f75a817/chicago-hospitals-launch-first-of-its-kind-breast-cancer-research-consortium-for-advanced-er-her2-cases 2025-09-02T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf396ac2f39b210c/medical-care-technologies-develops-patent-pending-ai-platform-for-smartphone-based-health-screening 2025-09-02T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/818b654195d8b35f/interferon-alpha-nasal-spray-reduces-covid-19-risk-by-40-in-cancer-patients 2025-09-02T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/293640ba78d94179/medipal-holdings-and-jcr-pharmaceuticals-partner-on-novel-gm2-gangliosidosis-therapy-jr-479 2025-09-02T21:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/56dbecdd87267e3c/seqone-acquires-congenica-to-create-global-leader-in-ai-powered-genomic-medicine 2025-09-02T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/aa0e4fe5c18e60c9/arrowhead-pharmaceuticals-secures-200-million-novartis-deal-for-alpha-synuclein-sirna-therapy 2025-09-02T21:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/00d0276ffd2e3b67/bridgebio-s-encaleret-achieves-calcium-normalization-in-80-of-post-surgical-hypoparathyroidism-patients 2025-09-02T21:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/4141a3bb5e9d36f0/geneseeq-secures-fda-510-k-clearance-for-comprehensive-425-gene-tumor-profiling-assay 2025-09-02T21:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/505704c562d97797/repurposed-drugs-successfully-clear-dormant-breast-cancer-cells-in-groundbreaking-clinical-trial 2025-09-02T21:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/13b70aabe53b3b36/ryvu-therapeutics-partners-with-biontech-to-accelerate-cancer-immunotherapy-trials-in-poland 2025-09-02T21:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/66cb1885a2e0b962/azelastine-nasal-spray-shows-promise-in-preventing-covid-19-infections-in-clinical-trial 2025-09-02T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/7698c388d1d203c8/johnson-johnson-s-varipulse-platform-achieves-99-7-effectiveness-with-zero-strokes-in-791-patient-atrial-fibrillation-study 2025-09-02T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/387f9d72268ab50c/vertex-pharmaceuticals-partners-with-enlaza-therapeutics-in-45-million-deal-to-develop-autoimmune-and-gene-editing-therapies 2025-09-02T17:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/4d901dd176e3c85c/cnipa-upholds-astrazeneca-s-dapagliflozin-crystal-patent-in-landmark-swiss-type-claims-ruling 2025-09-02T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/ac59e49fdbc3565c/hoth-therapeutics-ht-kit-shows-promising-preclinical-results-in-kit-driven-cancers 2025-09-02T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/b69a9bd476e13084/step-pharma-initiates-phase-1b-trial-of-dencatistat-for-essential-thrombocythaemia 2025-09-02T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/ad874c2c2ddfe34e/iggenix-completes-enrollment-for-first-in-human-trial-of-novel-peanut-allergy-antibody-therapy 2025-09-02T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/08b099711c8b53e4/neucore-bio-receives-350k-nih-grant-to-develop-exosome-based-gene-therapy-for-charcot-marie-tooth-disease 2025-09-02T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/fc010a60cef6a9c1/exmoor-pharma-forms-strategic-partnerships-to-strengthen-uk-cell-and-gene-therapy-manufacturing-pipeline 2025-09-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/f551f38944951533/j-j-s-impella-cp-heart-pump-demonstrates-16-3-mortality-reduction-in-10-year-follow-up-study 2025-09-02T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/e519b13dbb06a0cf/nanoscope-s-mco-010-receives-fda-rmat-and-five-ema-orphan-designations-for-retinal-dystrophies 2025-09-02T17:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/02f7d7cbc197d84e/kala-bio-names-todd-bazemore-as-permanent-ceo-ahead-of-pivotal-phase-2b-trial-readout 2025-09-02T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/492492ec0bb8d777/aera-therapeutics-names-bill-querbes-as-chief-scientific-officer-to-advance-genetic-medicine-pipeline 2025-09-02T17:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/bfd9d0515f445bcb/biotech-veterans-launch-corsera-health-with-annual-rnai-drug-to-prevent-cardiovascular-disease 2025-09-02T17:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/968324d2e8445571/quotient-sciences-and-cpi-form-joint-venture-to-accelerate-rna-drug-development-with-integrated-manufacturing-platform 2025-09-02T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/43144d4eec9c4439/alivamab-biologics-offers-royalty-free-access-to-transgenic-mouse-platform-for-human-antibody-discovery 2025-09-02T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/ae0cab2557db613c/dod-awards-963k-to-spri-for-breakthrough-extracellular-vesicle-study-in-osteoarthritis-treatment 2025-09-02T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/016bc70346e1d61c/fda-clears-medtronic-s-minimed-780g-system-for-abbott-sensor-integration-and-type-2-diabetes-use 2025-09-02T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/29896c1907b78f03/predicine-initiates-fda-premarket-approval-application-for-bladder-cancer-companion-diagnostic 2025-09-02T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/777ca14db1105c2b/medical-horizons-partners-with-bowhead-health-to-expand-ai-powered-clinical-trial-matching-across-italy-turkey-and-cyprus 2025-09-02T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/5f05d4119efbaa5b/glenmark-launches-first-generic-eribulin-mesylate-injection-in-66-3-million-market 2025-09-02T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/b63799c8c0c20203/zenas-biopharma-secures-300-million-royalty-deal-with-royalty-pharma-for-obexelimab-development 2025-09-02T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/5d9d1910b106853c/vtv-therapeutics-raises-80-million-to-advance-phase-3-trial-of-type-1-diabetes-drug-cadisegliatin 2025-09-02T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ad882ef142c20a5/sun-pharma-advances-cancer-drug-pipeline-with-unloxcyt-launch-planned-for-fy26 2025-09-02T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/64f8e0a78dae0891/genentech-partners-with-omass-therapeutics-in-400m-ibd-drug-development-deal 2025-09-02T13:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/689bf23fb9ac6c03/spleen-targeted-mrna-vaccine-shows-promise-against-hepatocellular-carcinoma-in-preclinical-studies 2025-09-02T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/53608e8c3534fdeb/breakthrough-antibody-therapy-shows-promise-against-treatment-resistant-breast-cancer 2025-09-02T13:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/8fc2a57249da1162/obi-pharma-initiates-phase-1-2-trial-for-novel-trop2-targeted-adc-obi-902-in-advanced-solid-tumors 2025-09-02T13:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/7d52b2ae95716d63/olema-oncology-and-pfizer-launch-phase-1b-2-trial-combining-palazestrant-with-atirmociclib-for-er-her2-metastatic-breast-cancer 2025-09-02T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/183d7bdfa161f834/charm-therapeutics-raises-80m-to-advance-ai-designed-menin-inhibitor-for-aml-treatment 2025-09-02T13:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/3df7a85995186cb6/novaremed-completes-patient-enrollment-in-nih-funded-phase-2b-trial-of-non-opioid-nispomeben-for-diabetic-neuropathy-pain 2025-09-02T13:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/2477a4426531dfe2/encoded-therapeutics-receives-fda-rmat-designation-for-etx101-gene-therapy-in-dravet-syndrome 2025-09-02T13:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/3a4fdbb56582641a/terumo-bct-and-pwc-belgium-launch-initiative-to-address-limited-access-to-advanced-cell-and-gene-therapies-in-europe 2025-09-02T13:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/8610477e9850654b/zymeworks-discontinues-zw171-mesothelin-targeted-t-cell-engager-after-phase-1-safety-concerns 2025-09-02T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/5fdbcda7cf3b17bc/nano-nuclear-energy-secures-1-25m-afwerx-contract-for-military-microreactor-deployment-study 2025-09-02T13:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/b3a4c4eb1f304ace/servier-and-ideaya-biosciences-strike-530m-partnership-for-uveal-melanoma-drug-darovasertib 2025-09-02T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/ab57295daa69ab7f/united-therapeutics-tyvaso-meets-primary-endpoint-in-phase-3-ipf-trial-demonstrating-significant-lung-function-improvement 2025-09-02T13:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/65315033b0fea5f2/hemex-expands-global-clinical-network-alliance-to-strengthen-end-to-end-cro-capabilities 2025-09-02T13:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/88b6b15012d0f3e9/pharming-group-appoints-kenneth-lynard-as-chief-financial-officer-to-strengthen-rare-disease-growth-strategy 2025-09-02T09:13:46+00:00 hourly 0.9 https://trial.medpath.com/news/d92d20f63e19a8d9/brenus-pharma-initiates-first-in-human-trial-of-stc-1010-immunotherapy-for-advanced-colorectal-cancer 2025-09-02T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/f4995cc5d891d730/citryll-initiates-phase-iia-trial-of-first-in-class-net-targeting-antibody-cit-013-for-rheumatoid-arthritis 2025-09-02T09:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/f69166ee785bc2eb/lantheus-advances-dual-alzheimer-s-diagnostic-strategy-with-tau-and-beta-amyloid-pet-imaging-agents 2025-09-02T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/9f860c545be0909f/qiagen-receives-fda-clearance-for-high-throughput-qiastat-dx-rise-syndromic-testing-system 2025-09-02T09:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/071410540cb2150e/hengrui-medicine-receives-china-s-first-ezh2-inhibitor-approval-for-hematological-malignancies 2025-09-02T06:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/2e6ca7cfa21d45b1/nsclc-molecular-testing-faces-critical-barriers-as-targeted-therapies-expand 2025-09-02T06:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/1b528fa73ca54c16/strata-excimer-laser-combined-with-jak-inhibitors-shows-100-response-rate-in-251-patient-vitiligo-trial 2025-09-02T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/d4b41f08f0150997/pharmaceutical-industry-accelerates-sustainable-packaging-adoption-as-environmental-pressures-mount 2025-09-02T02:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/9363d2067f0b8cce/oxford-university-launches-ps118m-ai-powered-vaccine-research-program-against-antibiotic-resistant-bacteria 2025-09-02T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/5a74bbfb0774c8b0/mission-hospital-completes-first-in-human-trial-of-emstop-stroke-prevention-device-for-heart-valve-surgery 2025-09-02T01:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/3f4100620020dffe/oslo-university-hospital-launches-phase-2-trial-comparing-ilb-r-to-standard-als-treatment 2025-09-02T01:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/42eaf6ba5697e9d0/hydrogel-based-mrna-cancer-vaccine-platform-shows-promise-for-enhanced-immune-response 2025-09-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e014dfe4c8c0f40f/stem-cell-derived-young-immune-cells-reverse-alzheimer-s-and-aging-signs-in-preclinical-study 2025-09-01T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/95dda0a3d7306efe/intellia-therapeutics-gains-momentum-as-ark-invest-and-institutional-investors-back-crispr-gene-editing-platform 2025-09-01T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/43725e46b8e58833/nfl-biosciences-nfl-101-demonstrates-significant-efficacy-in-phase-ii-smoking-cessation-trial 2025-09-01T21:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/0f1d81bf4a4c7e9f/tacsi-trial-challenges-dual-antiplatelet-therapy-after-cabg-shows-no-benefit-over-aspirin-alone 2025-09-01T21:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/de426748d2d5235a/trump-demands-covid-19-drug-data-transparency-as-cdc-leadership-crisis-deepens 2025-09-01T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/78eabf9a5eee95d8/novo-nordisk-partners-with-apollo-clinics-to-launch-comprehensive-obesity-management-programme-across-india 2025-09-01T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/2ed7c5e11e580e4a/high-court-strikes-out-sandoz-s-ps3-9-million-profit-claim-against-bayer-in-rivaroxaban-patent-dispute 2025-09-01T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/e4cb465a007a2edc/immupharma-files-groundbreaking-patent-for-p140-immunormalizer-targeting-type-m-immune-disorder 2025-09-01T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/7d86400fa1f91ca7/pharma-equity-group-receives-regulatory-approval-for-phase-ii-trial-of-rnx-011-in-secondary-peritonitis 2025-09-01T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/5c50f3ccf4447df4/fda-grants-first-ever-waiver-of-clinical-efficacy-studies-for-monoclonal-antibody-biosimilars 2025-09-01T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/217c572cdaffae7d/shanghai-henlius-biotech-receives-fda-approval-for-two-denosumab-biosimilars-for-osteoporosis-treatment 2025-09-01T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/d6a9c2ae313833ee/immunotherapy-shows-promise-for-small-cell-carcinoma-of-the-esophagus-dual-center-study-reveals 2025-09-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3954c04edb4dd9b/mexico-s-patent-office-includes-second-use-pharmaceutical-patents-in-linkage-gazette-for-first-time 2025-09-01T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/5ad3c2c3fd8c7aab/cyted-health-secures-eur37-5m-series-b-to-advance-esophageal-cancer-diagnostics-platform 2025-09-01T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/6d9b1063681e95f6/sacubitril-valsartan-shows-superior-efficacy-over-enalapril-in-first-prospective-trial-for-chagas-disease-heart-failure 2025-09-01T13:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/ea88e0ec08720d6c/saudi-us-collaboration-develops-smart-multi-compartment-capsule-for-personalized-drug-delivery 2025-09-01T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/e5b40d5c09ec527d/eurofins-viracor-biopharma-expands-operations-with-new-96000-sq-ft-state-of-the-art-facility 2025-09-01T13:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/e8978c9d72cfb8ad/fda-accepts-first-non-invasive-surrogate-endpoint-for-mash-clinical-trials 2025-09-01T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/d486a2ca71080c83/island-pharmaceuticals-secures-fda-meeting-for-galidesivir-fast-track-approval-under-animal-rule-pathway 2025-09-01T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/5e9cd1b37c88b778/fda-approves-weekly-autoinjector-for-eisai-s-alzheimer-s-drug-leqembi-enabling-at-home-treatment 2025-09-01T13:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/437fbbd2dd539dfb/uk-drug-pricing-negotiations-collapse-threatening-access-to-innovative-medicines 2025-09-01T13:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/3cc8864435687c99/real-world-data-confirms-pepaxti-efficacy-in-heavily-pretreated-multiple-myeloma-patients 2025-09-01T09:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/c1fea5602c1b501e/searle-secures-pakistani-regulatory-approval-for-denosumab-biosimilar-injections 2025-09-01T09:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/d098c4336bbae25f/tme-pharma-secures-eur2-35m-in-funding-to-advance-cancer-and-eye-disease-therapies 2025-09-01T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/10c9a9f2aa6e7c24/biophytis-advances-bio101-into-phase-2-obesity-trial-targeting-muscle-wasting-in-164-patients 2025-09-01T09:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/ce6bc42be9d56718/alone-af-trial-shows-discontinuing-anticoagulants-after-successful-afib-ablation-reduces-bleeding-risk 2025-09-01T01:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/271bfad67c5327c8/medpacto-s-vactosertib-achieves-complete-remission-in-osteosarcoma-phase-2-trial 2025-09-01T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/b50ff0d2ec615d7a/remote-ecg-patch-screening-shows-modest-increase-in-atrial-fibrillation-detection-in-high-risk-older-adults 2025-08-31T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/af515fda1c83d7f3/ucb-presents-comprehensive-epilepsy-research-portfolio-at-international-epilepsy-congress-2025 2025-08-31T21:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/964883c190d805ae/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-for-coronary-applications 2025-08-31T17:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/1fa1b01ed730d085/arcturus-therapeutics-advances-mrna-therapeutics-pipeline-with-strong-financial-performance-and-strategic-focus 2025-08-31T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/d5395d826861ac68/novartis-achieves-phase-iii-success-for-ianalumab-in-sjogren-s-disease-marking-potential-first-targeted-treatment 2025-08-31T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/692bdd44562b819a/tenaya-therapeutics-reveals-critical-risk-factors-in-largest-pediatric-mybpc3-associated-hcm-study 2025-08-31T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/c88b81de0589620e/japan-approves-first-over-the-counter-emergency-contraceptive-pill-after-years-of-regulatory-delays 2025-08-31T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/d4e55763d3d1e6b7/statins-show-promise-as-repurposed-therapy-for-colorectal-cancer-treatment 2025-08-31T13:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/b24785367696837d/wegovy-shows-57-greater-cardiovascular-risk-reduction-compared-to-tirzepatide-in-real-world-study 2025-08-31T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/3235267d6d42b3bc/swedepad-trials-show-drug-coated-devices-fail-to-improve-key-outcomes-in-peripheral-artery-disease 2025-08-31T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/c64727f57b1dc6c1/neurotech-s-nti164-cannabinoid-therapy-shows-promise-in-pediatric-neurological-disorders-with-positive-phase-ii-iii-data 2025-08-31T09:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/62abe33d673cea7c/immuron-reports-record-sales-growth-and-advances-multiple-clinical-programs-for-infectious-disease-treatments 2025-08-31T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/d566f9f7c15d2f0d/fda-approves-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-high-risk-populations 2025-08-31T09:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/cbabac4351a35bb0/shorter-dual-antiplatelet-therapy-shows-promise-in-heart-attack-patients-two-major-trials-challenge-current-guidelines 2025-08-31T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/92804e0b02f6790a/pharmacists-emerge-as-key-players-in-combating-vaccine-hesitancy-through-trust-building-and-clear-communication 2025-08-31T03:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/9ecd4fbff847e75c/medicaid-cuts-could-disrupt-pediatric-healthcare-access-amid-eligibility-confusion 2025-08-31T03:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/13a318f92c022cde/ivabradine-fails-to-prevent-myocardial-injury-after-noncardiac-surgery-in-prevent-mins-trial 2025-08-31T01:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/6422e79b1bd8b850/foresight-diagnostics-and-roche-resolve-patent-dispute-with-phased-seq-licensing-agreement-for-non-hodgkin-s-lymphoma-diagnostics 2025-08-31T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/012b29c67465e9a2/major-pharmacy-chains-limit-covid-19-vaccine-access-following-fda-approval-of-2025-2026-formulation 2025-08-30T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/5c91d6d73c6f49a0/astrazeneca-appoints-hematology-leader-anas-younes-as-chief-medical-officer 2025-08-30T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/e46549f8566e4c60/sun-pharma-receives-cdsco-approval-for-phase-iv-trial-of-high-dose-esomeprazole-dual-release-formulation 2025-08-30T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/8f06280a51960221/daiichi-sankyo-initiates-development-of-triple-combination-lipid-lowering-tablet-to-address-treatment-gaps 2025-08-30T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/5bc8d74773a03318/conflicting-results-emerge-from-large-scale-high-dose-influenza-vaccine-studies-in-older-adults 2025-08-30T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/3de8838797438aa2/altamira-therapeutics-advances-rna-delivery-platform-through-strategic-spin-off-and-circular-rna-innovation 2025-08-30T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/40e1e66c908715d1/dapa-act-hf-timi-68-trial-shows-promise-for-in-hospital-sglt2-inhibitor-initiation-despite-missing-primary-endpoint 2025-08-30T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/4320edcf9e404b6d/alnylam-advances-heart-drug-zilebesiran-to-phase-3-trial-despite-mid-stage-statistical-miss 2025-08-30T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/280dc41251ca548f/alnylam-s-zilebesiran-advances-to-phase-iii-zenith-trial-for-hypertension-treatment 2025-08-30T17:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/d57a0b52680c4e6c/conflicting-beta-blocker-trial-results-challenge-standard-heart-attack-treatment-guidelines 2025-08-30T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/e7dd7872e9b983f1/roche-and-alnylam-advance-zilebesiran-to-phase-iii-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2025-08-30T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/173a9c5a2e149816/olezarsen-achieves-60-triglyceride-reduction-in-phase-3-trial-for-cardiovascular-risk-patients 2025-08-30T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/a0a4ab5220dd285e/real-world-evidence-demonstrates-superior-cardiovascular-and-renal-benefits-of-glp-1-receptor-agonists-in-high-risk-patients 2025-08-30T17:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/1a801248a2bc18da/exercise-and-cognitive-behavioral-therapy-show-promise-for-treating-broken-heart-syndrome-in-world-first-trial 2025-08-30T13:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/146bfcf989165b33/aurobindo-pharma-subsidiaries-receive-mixed-fda-inspection-results-with-vai-classification-for-api-facility 2025-08-30T13:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/29b9a9ae00a25ad6/teva-receives-fda-approval-for-generic-saxenda-targeting-165-million-weight-management-market 2025-08-30T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/db421aa1a8cbccec/mavacamten-fails-to-show-significant-benefit-in-non-obstructive-hypertrophic-cardiomyopathy-trial 2025-08-30T09:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/73fefc52ca1ee13d/mrna-therapeutics-cdmo-market-projected-to-reach-9-billion-by-2030-amid-growing-demand-for-specialized-manufacturing 2025-08-30T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/8d228cb3fa963c0e/yd-bio-limited-goes-public-on-nasdaq-advancing-dna-methylation-cancer-detection-and-exosome-therapies 2025-08-30T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/c5147685d3bda804/india-streamlines-drug-development-process-with-digital-applications-and-faster-approval-timelines 2025-08-30T05:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/d71094744ca0b5fa/exelixis-promotes-dana-aftab-to-lead-consolidated-r-d-operations-amid-strategic-restructuring 2025-08-30T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/8d62a7f56d449d03/india-reports-1705-clinical-trial-deaths-since-2021-as-safety-concerns-mount 2025-08-30T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/f26b4a07704f0a7a/nice-approves-guselkumab-for-moderate-to-severe-ulcerative-colitis-and-crohn-s-disease 2025-08-30T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/2e24ff91f85470e9/lupin-challenges-ars-pharmaceuticals-neffy-patents-with-generic-application-filing 2025-08-30T01:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/3607d7250c684f05/cyted-health-secures-44m-series-b-to-expand-esophageal-cancer-diagnostics-platform-in-us-market 2025-08-30T01:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/fb3068cedae48029/sanofi-s-wayrilz-becomes-first-btk-inhibitor-approved-for-immune-thrombocytopenia-treatment 2025-08-30T01:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/6f18f3d0708abad1/axsome-submits-fda-application-for-axs-05-in-alzheimer-s-disease-agitation-following-positive-phase-3-results 2025-08-30T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/43295989f5234719/bempedoic-acid-receives-highest-esc-eas-guideline-recommendation-for-cardiovascular-risk-reduction 2025-08-29T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/bca1177a264d8cca/sycamore-partners-completes-11-45-per-share-acquisition-of-walgreens-boots-alliance 2025-08-29T21:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/f624e6b2413c0992/liposome-development-services-market-projected-to-reach-2-34-billion-by-2035-as-drug-delivery-challenges-drive-industry-growth 2025-08-29T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/8f7911334c27ce4a/phase-4-trial-demonstrates-superior-efficacy-of-endoscopic-sinus-surgery-over-antibiotics-for-chronic-rhinosinusitis 2025-08-29T21:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/1aa2700e6fcef4be/gsk-receives-fda-orphan-drug-designation-for-autosomal-dominant-polycystic-kidney-disease-treatment 2025-08-29T21:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/707acb62a70a391e/korean-hair-loss-shampoo-becomes-first-to-gain-chinese-regulatory-approval 2025-08-29T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/ab2ecab60802e163/indena-and-tcg-greenchem-form-strategic-alliance-to-accelerate-adc-payload-linker-development 2025-08-29T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/fdff11b84fa19de7/lubiprostone-shows-promise-in-slowing-kidney-function-decline-in-phase-ii-ckd-trial 2025-08-29T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/815f8f6ad34d243b/fda-approves-medtronic-s-evolut-tavr-systems-for-expanded-redo-tavr-indication 2025-08-29T21:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/6a9e1e5cf0e6e344/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-metastatic-kidney-cancer 2025-08-29T16:58:20+00:00 hourly 0.9 https://trial.medpath.com/news/24b2f3573fba8959/nyu-researchers-develop-wireless-led-pill-for-non-invasive-gut-nerve-stimulation 2025-08-29T16:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/61dd5ebd4bbc482b/eli-lilly-partners-with-jd-health-for-direct-to-consumer-glp-1-drug-sales-in-china 2025-08-29T16:57:36+00:00 hourly 0.9 https://trial.medpath.com/news/295e6e922bcdbf3e/real-world-evidence-confirms-mepolizumab-s-efficacy-in-severe-eosinophilic-asthma-with-enhanced-benefits-for-comorbid-nasal-polyps 2025-08-29T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/52632a413dfa058e/neogenomics-wins-patent-dispute-against-natera-clears-path-for-radar-st-assay-commercialization 2025-08-29T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/047bb7806eba6980/orexo-to-share-patent-defense-strategies-following-victory-against-sun-pharmaceutical-in-us-court 2025-08-29T16:56:13+00:00 hourly 0.9 https://trial.medpath.com/news/1dec9891592807ac/digitoxin-reduces-death-and-hospitalization-risk-in-advanced-heart-failure-patients 2025-08-29T16:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/d920b88561e52ca9/johnson-johnson-halts-rheumatoid-arthritis-trial-for-nipocalimab-refocuses-on-rare-disease-markets 2025-08-29T16:53:20+00:00 hourly 0.9 https://trial.medpath.com/news/04b9f546eabf86f6/mgi-tech-and-jcbio-launch-strategic-partnership-to-advance-multi-omics-research-in-south-korea 2025-08-29T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/87e411ff75bd6f21/bicycle-toxin-conjugates-emerge-as-novel-cancer-drug-class-with-promising-clinical-results 2025-08-29T16:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/53b140a006826140/nhs-england-to-roll-out-chickenpox-vaccine-in-january-2026-as-part-of-new-mmrv-immunization-program 2025-08-29T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/a22561a31e58a337/everest-medicines-reports-strong-h1-2025-growth-with-advanced-mrna-platform-and-pipeline-expansion 2025-08-29T16:46:41+00:00 hourly 0.9 https://trial.medpath.com/news/f9e9cd682d324af4/fda-recommends-enhanced-brain-monitoring-for-alzheimer-s-patients-on-leqembi-following-six-early-deaths 2025-08-29T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/8903420875ce1ccc/zydus-therapeutics-reports-positive-phase-3-results-for-saroglitazar-in-primary-biliary-cholangitis 2025-08-29T16:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/7e4e4c5c2dc96b28/fosun-pharma-secures-exclusive-rights-to-accro-s-tyk2-jak1-inhibitor-ac-201-for-greater-china-in-21-8m-deal 2025-08-29T16:45:14+00:00 hourly 0.9 https://trial.medpath.com/news/325ca5fe6e98c51c/eisai-s-tazemetostat-receives-orphan-drug-designation-in-japan-for-rare-epithelioid-sarcoma 2025-08-29T16:43:47+00:00 hourly 0.9 https://trial.medpath.com/news/c45f9ddd6cbf223a/coopervision-s-misight-1-day-becomes-first-myopia-control-contact-lens-approved-in-japan 2025-08-29T16:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/7b3af44cb075b59b/fda-approved-shield-blood-test-shows-84-sensitivity-for-colorectal-cancer-detection-in-updated-clinical-data 2025-08-29T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/8dabde33a62df4a1/tetraspecific-antibodies-poised-for-first-fda-approval-by-2029-market-report-reveals 2025-08-29T12:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/86dee58579549652/spica-therapeutics-secures-eur1-million-vlaio-grant-to-advance-anti-cd163-monoclonal-antibody-for-cancer-treatment 2025-08-29T09:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/444cb44627247652/rna-polymerase-i-inhibitors-emerge-as-promising-cancer-therapy-with-pindnarulex-leading-clinical-development 2025-08-29T09:20:06+00:00 hourly 0.9 https://trial.medpath.com/news/9455271279834440/tasso-and-shemed-partner-to-deliver-personalized-glp-1-weight-loss-treatments-through-at-home-blood-testing 2025-08-29T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/9f78057995b965a3/alphamab-oncology-s-kn026-receives-breakthrough-therapy-designation-for-her2-positive-gastric-cancer-in-china 2025-08-29T09:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/880af079a2f9ea71/cinclus-pharma-launches-phase-iii-trial-for-novel-gerd-treatment-targeting-european-market 2025-08-29T09:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/90d4055a1e8d6849/fda-approves-foresee-s-camcevi-etm-21mg-for-advanced-prostate-cancer-treatment 2025-08-29T09:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/5b469338e8fa30f8/johnson-johnson-discontinues-nipocalimab-combination-therapy-for-rheumatoid-arthritis-after-phase-2a-trial-fails-to-show-added-benefit 2025-08-29T05:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/e0c2958167ba1d84/arcellx-reports-97-response-rate-in-multiple-myeloma-car-t-trial-targets-2026-commercial-launch 2025-08-29T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/22d30af1d57c1313/entera-bio-to-present-phase-2-osteoporosis-data-and-next-generation-oral-peptide-programs-at-september-2025-conferences 2025-08-29T05:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/c4c4d26142fe6d91/multidisciplinary-approach-drives-de-escalation-of-breast-cancer-surgery-through-targeted-axillary-management 2025-08-29T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/833e26f65fe3ad63/breath-sensor-shows-promise-for-non-invasive-diabetes-detection-in-early-clinical-testing 2025-08-29T02:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/387b49d16c9a3bb3/aavantgarde-reports-positive-phase-1-2-data-for-gene-therapy-aavb-081-in-usher-syndrome-type-1b 2025-08-29T02:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/1d147e361da7c711/psychedelic-medicines-approach-market-entry-as-late-stage-trials-advance 2025-08-29T02:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/040d6f3e807960e3/lifileucel-til-therapy-shows-disease-stabilization-in-advanced-head-and-neck-cancer-patients 2025-08-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/63ee5b434c21df35/mrna-lipid-nanoparticle-intrabodies-show-promise-against-rickettsial-infections-in-preclinical-studies 2025-08-29T02:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/4d7cc705ebe58a1b/real-world-study-confirms-effectiveness-of-cat-allergen-immunotherapy-for-respiratory-allergies 2025-08-29T02:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/132c4da17a88ec44/senate-advances-patent-reform-bill-that-could-revitalize-biotech-innovation-and-diagnostics 2025-08-29T02:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/f339425b2fe0508a/phase-1-2-study-reports-final-results-for-cd123-targeted-tagraxofusp-in-relapsed-refractory-myelofibrosis 2025-08-29T02:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/4ae2cdca923aaf64/gastric-cancer-pipeline-shows-robust-growth-with-220-therapies-in-development-across-200-companies 2025-08-29T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/14cbf94e050ffc56/novel-selenium-enhanced-exosome-therapy-shows-promise-for-traumatic-cns-injuries 2025-08-29T02:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/b31268d1f83a5e9c/leukemia-stem-cell-test-shows-superior-prediction-of-aml-relapse-after-transplant 2025-08-28T22:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/880c1e323cb16315/first-in-class-stat3-inhibitor-shows-promise-in-feline-head-and-neck-cancer-trial-with-human-applications 2025-08-28T22:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/1f23f6bf405398fa/novel-frizzled-7-antibody-shows-promise-against-wilms-tumor-through-wnt-pathway-disruption 2025-08-28T22:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/a9436b9567508e95/abeona-therapeutics-expands-manufacturing-capacity-following-fda-approval-of-first-gene-therapy-for-rare-skin-disorder 2025-08-28T22:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/eff0744e6fcd514d/nih-awards-8-4-million-to-ohsu-scientists-to-develop-hiv-cure-through-study-of-three-cured-patients 2025-08-28T22:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/4e61ba465667f877/lyme-disease-pipeline-shows-promise-with-7-therapies-in-development-as-valneva-pfizer-vaccine-advances 2025-08-28T22:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/caabc2ddc7e3a07a/raina-biosciences-publishes-breakthrough-ai-platform-for-mrna-therapeutics-in-science 2025-08-28T22:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/4436265be1261117/photopharmics-forms-commercial-advisory-board-to-guide-fda-breakthrough-device-launch-for-parkinson-s-disease 2025-08-28T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/ddf4e83a5a935447/exelixis-closes-pennsylvania-facility-cuts-130-jobs-in-strategic-consolidation 2025-08-28T18:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/40d75395f010373d/novo-nordisk-partners-with-replicate-bioscience-in-550m-self-replicating-rna-deal-for-obesity-and-diabetes 2025-08-28T18:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/eaf11556b6c9a785/novo-nordisk-partners-with-replicate-bioscience-in-550m-deal-for-self-replicating-rna-platform 2025-08-28T18:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/596e2b8425562b83/cytomed-therapeutics-launches-longevitybank-to-advance-cord-blood-derived-nk-cell-immunotherapies 2025-08-28T18:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/a52ae108bfb4c128/igc-pharma-receives-patent-allowance-for-thc-microdose-treatment-targeting-tourette-s-syndrome-and-speech-disorders 2025-08-28T18:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/ebbf1dc7eeb6b1eb/oncotelic-therapeutics-advances-clinical-pipeline-led-by-ceo-s-4-2b-patent-legacy 2025-08-28T18:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/0ceb08e0218ee8e7/stramsen-biotech-seeks-fda-approval-to-skip-phase-1-trials-for-plant-based-wound-care-drug-sbx1977 2025-08-28T18:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/be02148d0f1420af/personalized-als-drug-shows-breakthrough-results-slowing-disease-progression-by-more-than-half 2025-08-28T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/7fb74e3c15b056e6/clonogenic-hepatocytes-drive-liver-growth-and-enhance-pediatric-gene-therapy-efficacy 2025-08-28T18:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/921a02b29d8a7f4e/bioarctic-reports-strong-q3-2025-results-driven-by-leqembi-royalties-and-novartis-partnership 2025-08-28T18:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/7600702af0526cbd/iqvia-and-flagship-pioneering-form-strategic-alliance-to-accelerate-biotech-innovation-through-ai-powered-drug-development 2025-08-28T18:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/4bcf4dc6a7275fb7/smartlabs-and-sonrai-analytics-form-strategic-ai-partnership-to-accelerate-precision-medicine-discovery 2025-08-28T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fbed591f61aa225f/teva-launches-first-generic-glp-1-weight-loss-drug-as-fda-approves-generic-saxenda 2025-08-28T18:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/da5b2d49b28dbade/first-in-class-stat3-inhibitor-shows-promise-in-feline-cancer-trial-with-human-applications 2025-08-28T18:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/9e4e86e6edf62b47/uc-davis-health-performs-world-s-first-procedure-with-abbott-s-advanced-mitraclip-and-triclip-g5-valve-repair-system 2025-08-28T18:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/cc71e5866a29c5a7/breakthrough-tuberculosis-drug-targets-and-novel-therapeutic-strategies-show-promise-against-drug-resistant-strains 2025-08-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c5bce588ee51d72/immuneoncia-partners-with-wuxi-biologics-to-advance-anti-pd-l1-cd47-bispecific-antibody-ioh-001 2025-08-28T14:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/76b533f32f98995d/eli-lilly-halts-uk-mounjaro-shipments-ahead-of-170-price-increase 2025-08-28T14:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/1cfabcf7c02b98eb/hong-kong-approves-four-new-drugs-under-accelerated-1-mechanism-including-iga-nephropathy-treatment 2025-08-28T14:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/28d25e2dd2edb37b/nih-awards-2-8-million-grant-to-develop-next-generation-brain-implant-for-drug-resistant-epilepsy 2025-08-28T14:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/00f63158262a2487/ensilitech-raises-ps4-5m-to-eliminate-cold-chain-dependency-with-room-temperature-stable-biopharmaceuticals 2025-08-28T14:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/43eecb9c5d1a4081/celltrion-expands-biosimilar-portfolio-in-vietnam-s-7-3-billion-biopharmaceutical-market 2025-08-28T14:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/8b1baa27c34354c9/vanda-pharmaceuticals-receives-fda-orphan-drug-designation-for-novel-jak2-selective-antisense-therapy-vgt-1849b-in-polycythemia-vera 2025-08-28T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/160bc3699efd43eb/texas-house-passes-bill-allowing-over-the-counter-ivermectin-sales-without-prescription 2025-08-28T10:13:50+00:00 hourly 0.9 https://trial.medpath.com/news/9aceeb92ec0d946e/fda-approves-covid-19-vaccines-for-high-risk-populations-with-mandatory-post-marketing-studies 2025-08-28T10:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/7d12eec91d5e5c27/gc-biopharma-advances-two-dose-varicella-vaccine-barycela-to-phase-3-trial-in-thailand 2025-08-28T10:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/b2df9c67aaaaffa7/cannabis-based-medical-products-show-sustained-sleep-quality-improvements-in-18-month-insomnia-study 2025-08-28T10:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/a00c58268dd06160/circio-s-circvec-technology-achieves-40x-enhancement-in-aav-gene-therapy-vectors 2025-08-28T10:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/7421ffabecac1ba1/canadian-federal-court-of-appeal-rules-on-patent-register-timing-in-bayer-vs-amgen-case 2025-08-28T10:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/4704c5b89c75a1e2/network-meta-analysis-reveals-optimal-chinese-herbal-preparations-for-gastric-cancer-treatment 2025-08-28T10:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/9b4929e78fcc3381/fda-orphan-drug-incentives-and-patient-advocacy-drive-rare-disease-drug-development 2025-08-28T10:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/69296e73b303549f/biophytis-receives-ema-and-belgian-regulatory-approval-for-phase-3-sarcopenia-trial 2025-08-28T10:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/9314269c86c506c0/mrd-testing-emerges-as-key-tool-for-value-based-care-in-multiple-myeloma-treatment 2025-08-28T10:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/cd87a4f8305462fb/knowledge-gaps-persist-in-understanding-adc-efficacy-for-nsclc-brain-metastases 2025-08-28T10:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/6d088ee65b5be42a/mannkind-and-united-therapeutics-expand-partnership-for-second-pulmonary-hypertension-inhaled-therapy 2025-08-28T06:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/cf577cf934c9088a/acrobiosystems-and-daan-biotherapeutics-form-strategic-alliance-to-accelerate-precision-immuno-oncology-development 2025-08-28T06:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/0964d22cd68eee5e/baylor-genetics-rna-sequencing-studies-show-24-diagnostic-success-rate-for-previously-undiagnosed-rare-diseases 2025-08-28T03:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/511c7add7ec2ed45/intensive-gum-disease-treatment-reduces-arterial-thickening-in-randomized-clinical-trial 2025-08-28T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/6760b3ad9668b897/tct-2025-unveils-28-late-breaking-cardiovascular-trials-featuring-novel-drug-eluting-technologies-and-ai-enabled-diagnostics 2025-08-28T02:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/0fbde3ab14beae1e/first-in-concept-adc-micvotabart-pelidotin-achieves-50-response-rate-in-head-and-neck-cancer-earns-fda-fast-track-designation 2025-08-28T02:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/5458666c86bc6980/tas-102-shows-promise-in-clearing-circulating-tumor-dna-in-colorectal-cancer-patients-with-minimal-residual-disease 2025-08-28T02:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/0537e70fa396fea2/leicester-royal-infirmary-expands-aseptic-pharmacy-to-triple-cancer-treatment-production-capacity 2025-08-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd030d1fa1cd428f/federal-circuit-affirms-patent-priority-for-phmb-based-wound-treatment-in-first-aia-derivation-review 2025-08-27T21:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/441498a4f56f2957/fda-approves-pemigatinib-for-rare-fgfr1-rearranged-myeloid-lymphoid-neoplasms-following-stanford-led-phase-ii-trial 2025-08-27T21:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/85f7c0673a31c8a7/cartherics-secures-chinese-patent-for-enhanced-nk-cell-therapy-targeting-solid-tumors 2025-08-27T21:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/799e028059493959/decipher-genomic-test-predicts-chemotherapy-benefit-in-metastatic-prostate-cancer 2025-08-27T21:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/ebf93cbfa90416ea/researchers-identify-gene-signatures-to-predict-cdk4-6-inhibitor-response-in-hormone-positive-breast-cancer 2025-08-27T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/e34e62b96c397327/scientists-develop-laser-free-eye-surgery-alternative-using-electrical-current-to-reshape-cornea 2025-08-27T21:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/045bc7c85e76744b/neusoft-medical-systems-receives-nmpa-approval-for-china-s-first-photon-counting-ct-scanner 2025-08-27T21:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/0c2ea4c6fb33a2b6/cuny-researchers-develop-first-broad-spectrum-antiviral-targeting-viral-envelope-glycans 2025-08-27T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/9a3f771fe09b272f/mhra-launches-route-b-pilot-to-streamline-clinical-trial-modifications-ahead-of-2026-regulatory-overhaul 2025-08-27T21:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/2377ca2488454276/lilly-s-verzenio-demonstrates-significant-overall-survival-benefit-in-high-risk-early-breast-cancer 2025-08-27T18:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/c8cac875ada295bc/hope-biosciences-receives-first-fda-rmat-designation-for-multiple-sclerosis-stem-cell-therapy 2025-08-27T18:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/ea0d1fd05bf04e3b/prometheus-laboratories-partners-with-celltrion-to-validate-therapeutic-drug-monitoring-for-subcutaneous-infliximab 2025-08-27T18:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/6c075b13375b24e0/sarepta-therapeutics-shares-drop-10-following-new-liver-injury-report-for-gene-therapy-elevidys 2025-08-27T18:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/e935efbbc8a3c93f/allogeneic-cd19-car-t-cell-therapy-shows-promise-for-refractory-lupus-nephritis-in-phase-1-trial 2025-08-27T18:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/78ba80828f96ea4a/evommune-initiates-phase-2b-trial-of-oral-mrgprx2-antagonist-evo756-for-moderate-to-severe-atopic-dermatitis 2025-08-27T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/4f72a41008beda44/azitra-doses-first-patient-in-phase-1-2-trial-of-live-biotherapeutic-for-egfr-inhibitor-associated-rash 2025-08-27T18:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/1773ade44fe78021/minovia-therapeutics-secures-350000-grant-to-develop-blood-based-mitochondrial-biomarkers 2025-08-27T18:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/d971ca51a1867bc7/crispr-gene-therapy-exa-cel-delivers-sustained-quality-of-life-improvements-in-blood-disorders 2025-08-27T18:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/5e80f501e97d1d98/wugen-secures-115-million-to-advance-first-in-class-off-the-shelf-car-t-therapy-for-t-cell-malignancies 2025-08-27T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/a1a254b0040e1774/amylyx-s-amx0035-fails-mid-stage-trial-for-progressive-supranuclear-palsy 2025-08-27T18:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/c74b9d59624147b8/rafael-holdings-reports-78-success-rate-for-npc1-treatment-in-phase-3-pediatric-sub-study 2025-08-27T18:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/06ac0874b8f3a49b/moleculin-s-annamycin-shows-promising-survival-data-in-relapsed-aml-phase-1b-2-trial 2025-08-27T18:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/f8509d05027988e1/real-world-evidence-confirms-survival-benefits-of-immunotherapy-in-extensive-stage-small-cell-lung-cancer 2025-08-27T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/1a7890f67e5610fe/breath-analysis-technology-achieves-breakthrough-in-predicting-pneumonia-before-symptoms-appear 2025-08-27T18:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/94c588ce4c435ecc/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-central-airway-stenosis 2025-08-27T18:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/52d1d01c3c905e0e/ms-pharma-opens-first-biologics-manufacturing-facility-in-middle-east-with-50-million-saudi-arabia-investment 2025-08-27T18:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/05a47758dbbd5f2b/cleveland-clinic-deploys-ai-platform-to-accelerate-clinical-trial-recruitment-across-multiple-specialties 2025-08-27T17:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/1e19cbdca6484033/northwest-biotherapeutics-completes-strategic-acquisition-of-advent-bioservices-to-integrate-manufacturing-operations 2025-08-27T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/988e4e0704a75699/alivedx-advances-mosaiq-platform-in-us-market-with-fda-device-registration-and-vasculitis-test-submission 2025-08-27T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/bd4c92ed1d81cf87/circurna-partners-with-gatc-health-to-accelerate-circular-rna-therapeutics-using-ai-platform 2025-08-27T14:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/007566e3bfa00433/treos-bio-launches-pivotal-phase-ii-trial-for-polypepi1018-in-treatment-resistant-colorectal-cancer 2025-08-27T14:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/09aca16512211421/amylyx-discontinues-amx0035-development-for-progressive-supranuclear-palsy-after-phase-2b-trial-fails-to-meet-primary-endpoints 2025-08-27T14:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/598d55c4579e4c6b/starpharma-advances-dendrimer-drug-delivery-platform-with-genentech-partnership-and-clinical-progress 2025-08-27T14:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/d5d6f3b768308ad6/comprehensive-her2-breast-cancer-clinical-trials-report-2025-reveals-global-research-landscape 2025-08-27T14:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/e5e34e5ed778f857/cage-bio-initiates-phase-2-trial-of-first-in-class-dna-aptamer-therapy-cgb-600-for-vitiligo-treatment 2025-08-27T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/8fcc4ce2f41c2d36/glp-1-receptor-agonists-reduce-heart-failure-events-while-cutting-healthcare-carbon-emissions-by-2-billion-kilograms 2025-08-27T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/da02c49799a54c1a/global-pharma-investment-in-china-surges-to-48-5-billion-in-first-half-of-2025-doubling-2024-total 2025-08-27T10:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/56ae121504f87d12/osivax-secures-19-5m-barda-award-to-advance-universal-influenza-vaccine-ovx836 2025-08-27T10:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/66444f048376a8a6/bioversys-receives-ema-orphan-designation-for-novel-tuberculosis-combination-therapy 2025-08-27T09:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/a0136a9233ce5585/biotech-funding-surge-153m-for-programmable-mrna-cancer-therapy-leads-major-investment-round 2025-08-27T09:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/01d49981d72da231/neuren-pharmaceuticals-reports-record-daybue-royalties-as-rett-syndrome-therapy-sales-exceed-100-million-quarterly-milestone 2025-08-27T09:56:59+00:00 hourly 0.9 https://trial.medpath.com/news/3bbf8fbebe9703ad/altasciences-partners-with-evidence-matters-to-deploy-ai-enhanced-regulatory-writing-technology 2025-08-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4481030358814a71/us-trade-commission-bans-ultrahuman-and-ringconn-smart-rings-following-oura-health-patent-victory 2025-08-27T06:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/7fa5d80afacdd349/federal-appeals-court-reinstates-oregon-drug-price-transparency-law-after-phrma-challenge 2025-08-27T06:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/039ec02517994412/cancer-vaccines-show-promise-in-clinical-trials-for-glioblastoma-and-other-malignancies 2025-08-27T06:07:44+00:00 hourly 0.9